Clinical trial register · Poland

Clinical Trials in Katowice, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Poland and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2705 matching records held by the registry are in this view. Synced 28 Oct 2026, 03:18 UTC

2705

Studies in scope

all four open statuses

1389

Recruiting now

open to new participants

512

Lead sponsors

across recruiting studies

Top sites

Warsaw 1315 Krakow 882 Poznan 705 Gdansk 657 Lodz 619

Trials with a site in Katowice

Status

Study

Lead sponsor

Phase

Enrol

Sites in Poland

Start

Not yet open

A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies

NCT07789015Idiopathic Inflammatory Myopathies

DrugNerandomilast

Boehringer Ingelheim

Phase 3

270

Bialystok, Bydgoszcz, Katowice

2026-12-14

Not yet open

A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder

NCT07285798Irritability Associated With Autism Spectrum Disorder

DrugsKarX-EC·KarXT

Bristol-Myers Squibb

Phase 3

176

Poznan, Wroclaw, Warsaw, Gdansk, Szczecin, Katowice, Lublin, Zabrze

2026-10-02

Not yet open

Vortosiran in Atrial Fibrillation

NCT07870889Non-valvular Atrial Fibrillation (AF)

DrugsVortosiran·Apixaban

Ribocure Pharmaceuticals AB

Phase 2

150

Katowice, Krakow, Raszyn, Skorzewo, Warsaw, Wroclaw

2026-10-01

Recruiting

Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes

NCT07672769Higher Risk Myelodysplastic Syndromes

DrugsBexmarilimab·Azacitidine

Faron Pharmaceuticals Ltd

Phase 2

Katowice, Skórzewo, Warsaw

2026-10

Recruiting

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

NCT07648264Secondary Immune Deficiency

DrugHizentra

CSL Behring

Phase 3

Torun, Krakow, Gliwice, Katowice, Skorzewo (Poznan)

2026-09-15

Recruiting

A Study in Adults With Geographic Atrophy

NCT07606365Geographic Atrophy

DrugSTL303

Sitala Bio LTD

Phase 2

300

Bielsko-Biala, Bydgoszcz, Katowice, Krakow, Olsztyn, Poznan, Warsaw, Wałbrzych

2026-09-11

Recruiting

A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

NCT07623161Myelofibrosis, Anemia

DrugElritercept

Takeda

Phase 3

324

Poznan, Torun, Warsaw, Chorzów, Katowice, Lodz

2026-09-10

Recruiting

A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned

NCT07665450Multiple Myeloma

DrugsRamantamig·Bortezomib·Daratumumab·Lenalidomide

Janssen Research & Development, LLC

Phase 3

1,000

Katowice, Lublin

2026-09-09

Recruiting

A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

NCT07623200Essential Thrombocythemia

DrugINCA033989

Incyte Corporation

Phase 3

426

Gdansk, Katowice, Krakow, Lodz, Lublin, Warsaw, Wałbrzych

2026-09-08

Not yet open

Snoezelen Therapy in Adults With Alcohol Dependence and Adults With Schizophrenia

NCT07748078SCHIZOPHRENIA 1 (Disorder), Alcohol Use Disorder, Alcohol Dependence (Primary Condition)

The Jerzy Kukuczka Academy of Physical Education in Katowice

Not applicable

140

Katowice, Rybnik

2026-09-01

Not yet open

Impact of Respiratory Training on Reaction Time and Other Performance Components in Young Football Players.

NCT07737379Training Effectiveness, Training Efficiency, Football Players

The Jerzy Kukuczka Academy of Physical Education in Katowice

Not applicable

Katowice, Rybnik

2026-09-01

Not yet open

Basal Stimulation Therapy in Adults With Schizophrenia Requiring Institutional Care

NCT07769749SCHIZOPHRENIA 1 (Disorder)

The Jerzy Kukuczka Academy of Physical Education in Katowice

Not applicable

Katowice, Rybnik

2026-09-01

Not yet open

Effectiveness and Costs of Pressure Ulcer Treatment and the Quality of Life of Patients With Pressure Ulcers Receiving Home-Based and Institutional Care

NCT07763106Pressure Ulcer (PU), Pressure Ulcers, Bedsores, Decubitus Ulcer, Quality of Life, INSTITUTIONAL CARE

The Jerzy Kukuczka Academy of Physical Education in Katowice

Not applicable

Katowice, Rybnik

2026-09-01

Recruiting

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

NCT07743463Obesity, Overweight, Chronic Weight Management

DrugASC30 A1

Ascletis Pharma (China) Co., Limited

Phase 3

3,003

Biała Podlaska, Bydgoszcz, Częstochowa, Gdansk, Gdynia, Katowice, Krakow, Lodz

2026-08-31

Recruiting

Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment

NCT07691970Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus

DrugAnifrolumab

AstraZeneca

Phase 3

1,072

Bydgoszcz, Katowice, Kielce, Krakow, Ossy, Warsaw

2026-08-31

Recruiting

A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis

NCT07845487Ulcerative Colitis (UC), Severe Ulcerative Colitis, Moderate Ulcerative Colitis

DrugPALI-2108

Palisade Bio

Phase 2

204

Bydgoszcz, Elblag, Katowice, Kielce, Krakow, Kłodzko, Lodz, Lublin

2026-08-28

Recruiting

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

NCT07743450Obesity, Overweight, Chronic Weight Management, Type 2 Diabetes Mellitus

DrugASC30 A1

Ascletis Pharma (China) Co., Limited

Phase 3

1,560

Biała Podlaska, Bydgoszcz, Częstochowa, Gdansk, Gdynia, Katowice, Krakow, Lodz

2026-08-28

Recruiting

AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications

NCT07797335Type 2 Diabetes, Cardiovascular Risk

DrugZenagamtide

Novo Nordisk A/S

Phase 3

1,778

Lublin, Bialystok, Chorzów, Bolesławiec, Katowice, Libiąż, Lodz, Olsztyn

2026-08-24

Recruiting

A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)

DrugElecoglipron

AstraZeneca

Phase 3

6,950

Bialystok, Częstochowa, Gdynia, Katowice, Krakow, Poznan, Przemyśl, Radzionków

2026-08-24

Recruiting

A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

NCT07753993Chronic Kidney Disease

DrugElecoglipron

AstraZeneca

Phase 3

7,000

Będzin, Bialystok, Czeladź, Gmina Świecie, Katowice, Kwidzyn, Lodz, Lublin

2026-08-21

Recruiting

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

NCT07784270Obesity or Overweight, Diabetes Mellitus, Type 2

DrugLenbelintide

AstraZeneca

Phase 3

1,500

Bialystok, Elblag, Gdynia, Katowice, Krakow, Legnica, Lodz, Poznan

2026-08-20

Recruiting

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

NCT07784725Obesity or Overweight

DrugLenbelintide

AstraZeneca

Phase 3

2,500

Bialystok, Elblag, Gdynia, Katowice, Krakow, Legnica, Lodz, Poznan

2026-08-19

Not yet open

Clinical Validation of an Artificial Intelligence System for the Interpretation of Laboratory Test Results Combined With a Structured Medical History

NCT07810491Diagnostic Techniques and Procedures, Clinical Laboratory Techniques, Triage

Labplus Sp. z o.o.

Not applicable

899

Katowice

2026-08-19

Recruiting

A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.

NCT07619131Hypercholesterolaemia

DrugsRosuvastatin 1·Rosuvastatin 2

AstraZeneca

Phase 3

600

Częstochowa, Gdynia, Katowice, Lodz, Lublin, Warsaw

2026-08-12

Recruiting

BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)

NCT07625644Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma, Sclc

DrugsEtoposide·Atezolizumab·Carboplatin

SystImmune Inc.

Phase 3

550

Bialystok, Gdynia, Katowice, Lodz, Prabuty

2026-08-04

By invitation

Acute Effects of Bilateral Versus Unilateral Isometric Conditioning Activity on Jump Performance in Volleyball Players

NCT07709104Athletic Performance, Volleyball, Isometric Strength Training, Post Activation Potentiation

The Jerzy Kukuczka Academy of Physical Education in Katowice

Not applicable

Katowice

2026-07-23

Recruiting

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)

NCT06987539Generalized Myasthenia Gravis

DrugInebilizumab

Amgen

Phase 2

Bydgoszcz, Katowice

2026-07-21

Recruiting

DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

NCT07544654Extrapulmonary Neuroendocrine Cancer (epNEC)

DrugsObrixtamig·Etoposide·Carboplatin

Boehringer Ingelheim

Phase 3

390

Gdansk, Katowice

2026-07-10

Recruiting

Ravulizumab Outcomes in Polish Patients With aHUS

NCT07399730Atypical Hemolytic Uremic Syndrome

DrugRavulizumab

AstraZeneca

Observational

Gdansk, Katowice, Krakow, Lodz, Poznan, Warsaw, Wroclaw

2026-06-24

Recruiting

A Study of ARC-02 in B-cell NHL

NCT07691606B-cell Non Hodgkin Lymphoma

DrugRituximab

Taiho Oncology, Inc.

Phase 1

140

Katowice, Krakow, Skorzewo, Warsaw

2026-06-22

Recruiting

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.

NCT07596849Graves Disease

DrugEfgartigimod PH20

argenx

Phase 3

230

Krakow, Katowice, Bydgoszcz, Chrzanów, Lublin, Warsaw, Zamość

2026-06-10

Recruiting

An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED

NCT07519902Persistent Corneal Epithelial Defect

DrugCenegermin

Dompé Farmaceutici S.p.A

Phase 3

150

Lublin, Warsaw, Katowice

2026-06-02

Recruiting

A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction

NCT07192952Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)

DrugFinerenone

Bayer

Phase 3

117

Wroclaw, Warsaw, Gdansk, Katowice, Lodz

2026-06-01

Recruiting

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT07518186Multiple Myeloma

DrugsRamantamig·Teclistamab

Janssen Research & Development, LLC

Phase 3

700

Bydgoszcz, Gdansk, Katowice, Lublin, Warsaw, Wałbrzych

2026-05-31

Recruiting

A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis

NCT07470879Colitis, Ulcerative

DrugEtrasimod

Pfizer

Phase 2

Warsaw, Katowice

2026-05-28

Recruiting

A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

NCT07599813Atopic Dermatitis, Atopic, Dermatitis, Dermatitis, Atopic

Apollo Therapeutics Ltd

Phase 2

280

Bydgoszcz, Chojnice, Gdansk, Katowice, Kielce, Lublin, Piotrkow Trybunalski, Poznan

2026-05-28

Recruiting

A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)

DrugsPelabresib·Ruxolitinib

Novartis Pharmaceuticals

Phase 3

460

Gdansk, Katowice, Lublin, Skorzewo, Torun, Warsaw, Wałbrzych

2026-05-27

Recruiting

A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

NCT07564414Obesity, Type 2 Diabetes

DrugsCagriSema·Semaglutide

Novo Nordisk A/S

Phase 3

2,500

Bialystok, Bydgoszcz, Dębica, Katowice, Krakow, Poznan, Rzeszów, Warsaw

2026-05-21

Recruiting

A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

NCT07393282High Risk Smoldering Multiple Myeloma (HR-SMM)

DrugsLinvoseltamab·Darzalex·Daratumumab

Regeneron Pharmaceuticals

Phase 3

270

Katowice

2026-05-21

Recruiting

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

NCT07413939HER2-positive Breast Cancer

DrugsZN-A-1041·Tucatinib·Trastuzumab·Capecitabine

Hoffmann-La Roche

Phase 2/3

650

?ód?, Katowice, Krakow, Olsztyn, Opole, Późna, Tomaszów Mazowiecki, Wroc?aw

2026-05-21

Recruiting

A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions

NCT07422480Myelodysplastic Syndrome, Anemia

DrugsElritercept·Epoetin Alfa

Takeda

Phase 3

300

Wroclaw, Krakow, Warsaw, Katowice, Skorzewo

2026-05-21

Recruiting

A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis

NCT07501702Myasthenia Gravis, Generalized

DrugPovetacicept

Vertex Pharmaceuticals Incorporated

Phase 2

Bydgoszcz, Katowice, Poznan, Warsaw

2026-05-13

Recruiting

Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)

NCT07318597Pulmonary Arterial Hypertension (PAH)

Regeneron Pharmaceuticals

Phase 2

Poznan, Bialystok, Katowice, Lodz

2026-05-06

Recruiting

A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)

NCT07545759Irritable Bowel Syndrome, Diarrhea

DrugBrenipatide

Eli Lilly and Company

Phase 2

531

Katowice, Piotrkow Trybunalski, Poznan, Szczecin, Warsaw, Zamość

2026-05-06

Recruiting

A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

NCT07483099Crohn Disease

DrugsLY4395089·Mirikizumab

Eli Lilly and Company

Phase 2

Katowice, Krakow, Lublin, Poznan, Siedlce, Szczecin, Warsaw, Zamość

2026-05-04

Recruiting

A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

NCT07483073Colitis, Ulcerative, Crohn Disease

DrugsLY4395089·Mirikizumab

Eli Lilly and Company

Phase 2

Katowice, Krakow, Lublin, Poznan, Siedlce, Szczecin, Warsaw, Zamość

2026-05-04

Recruiting

A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)

NCT07519772Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

DrugMK-1045

Merck Sharp & Dohme LLC

Phase 1/2

280

Krakow, Warsaw, Gliwice, Katowice

2026-05-03

Recruiting

Intra-Articular Allocetra in Patients With Primary Knee Osteoarthritis

NCT07580716Primary Knee Osteoarthritis

DrugAllocetra

Enlivex Therapeutics Ltd.

Phase 2

182

Bytom, Katowice, Krakow, Poznan, Radom, Swidnica, Warsaw, Wroclaw

2026-05-01

Recruiting

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

NCT07226843Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma

DrugRituximab

Eli Lilly and Company

Phase 1

460

Katowice, Krakow, Skorzewo, Warsaw

2026-04-17

Recruiting

Visugromab in Cachexia International Trial

NCT07112196Cancer-associated Cachexia

DrugsVisugromab·Visugromab RDE

CatalYm GmbH

Phase 2/3

518

Katowice, Krakow, Lodz, Lublin, Warsaw, Wroclaw

2026-04-16

Recruiting

A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

NCT07430306Systemic Lupus Erythematosus

DrugAnifrolumab

AstraZeneca

Phase 3

245

Bydgoszcz, Częstochowa, Katowice, Krakow, Lodz, Lublin, Nadarzyn, Nowa Sól

2026-04-13

Recruiting

A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents

NCT07424404Schizophrenia, Autism-Related Irritability

DrugsKarX-EC·KarXT

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

400

Poznan, Wroclaw, Warsaw, Gdansk, Szczecin, Katowice, Lublin, Zabrze

2026-04-07

Recruiting

Confirmatory Clinical Study in Active Ulcerative Colitis

NCT07296315Colitis, Ulcerative

MRM Health NV

Phase 2

204

Bydgoszcz, Katowice, Krakow, Poznan, Sopot, Warsaw, Wroclaw

2026-04-03

Recruiting

A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

NCT07540221CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)

DrugsGamunex-C·Xembify

Grifols Therapeutics LLC

Phase 3

Bydgoszcz, Katowice, Krakow, Wroclaw

2026-04-02

Recruiting

A Study of MB-001 in Moderately to Severely Active Ulcerative Colitis

NCT07374471Ulcerative Colitis (UC)

Mage Biologics

Phase 1/2

100

Katowice, Warsaw, Wroclaw

2026-04-01

Recruiting

A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)

NCT07503873Multiple Sclerosis

DrugUblituximab

TG Therapeutics, Inc.

Phase 2

350

Bydgoszcz, Katowice, Kielce, Krakow, Lodz, Olsztyn, Poznan, Warsaw

2026-04-01

Recruiting

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)

NCT07440225Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration

DrugsTiespectus·Eylea·Aflibercept

EyeBiotech Ltd.

Phase 2/3

960

Bydgoszcz, Gdansk, Katowice, Krakow, Olsztyn, Tarnowskie Góry

2026-03-27

Recruiting

Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines

NCT07415551Allergic Diseases, Chronic Spontaneous Urticaria (CSU)

Yuhan Corporation

Phase 2

150

Poznan, Krakow, Tarnów, Wroclaw, Lublin, Opole, Bialystok, Katowice

2026-03-26

Recruiting

LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe

DrugZotemtegrast

Eli Lilly and Company

Phase 2

1,431

Chorzów, Katowice, Kielce, Krakow, Lodz, Malbork, Nowy Targ, Poznan

2026-03-26

Recruiting

A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

NCT07067463Multiple Sclerosis (MS) Primary Progressive

DrugOrelabrutinib

Zenas BioPharma (USA), LLC

Phase 3

705

Bydgoszcz, Zabrze, Katowice, Plewiska, Poznan, Gdansk, Lublin, Nowa Sól

2026-03-23

Recruiting

A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

NCT07299019Secondary Progressive Multiple Sclerosis

DrugOrelabrutinib

Zenas BioPharma (USA), LLC

Phase 3

990

Bydgoszcz, Nowa Sól, Rzeszów, Katowice, Poznan, Lodz, Lublin, Szczecin

2026-03-23

Recruiting

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

NCT07361497Non-small Cell Lung Cancer (NSCLC)

DrugsPumitamig·Durvalumab

Bristol-Myers Squibb

Phase 3

850

Lublin, Opole, Przemyśl, Katowice

2026-03-16

Recruiting

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

NCT07361510Non-Small Cell Lung Cancer (NSCLC)

DrugsPumitamig·Pembrolizumab

Bristol-Myers Squibb

Phase 3

750

Opole, Przemyśl, Katowice, Lodz

2026-03-12

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)

NCT07282574Progressive Multiple Sclerosis

DrugOcrelizumab

Hoffmann-La Roche

Phase 2

360

Poznan, Rzeszw, Katowice, ?ory, ?ód?, Bydgoszcz, Gda?sk, Kielce

2026-03-10

Recruiting

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT07218341Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic

DrugsIdelalisib·Pirtobrutinib

Eli Lilly and Company

Phase 4

150

Brzozów, Bydgoszcz, Katowice

2026-03-09

Recruiting

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

NCT07438496Lupus Erythematosus, Systemic

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

600

Bydgoszcz, Bytom, Katowice, Krakow, Nadarzyn, Nowa Sól, Poznan, Płońsk

2026-03-05

Recruiting

Somatic and Psychological Profile of Athletes Across Seasonal Cycles

NCT07709273Eating Behavior, Perfectionism

The Jerzy Kukuczka Academy of Physical Education in Katowice

Observational

300

Katowice

2026-03-02

Active, closed

A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)

NCT07400653Obesity, Overweight and/or Obesity, Overweight, Diabetes, Type 2

DrugBerobenatide

Pfizer

Phase 3

1,078

Lodz, Bialystok, Bydgoszcz, Chojnice, Częstochowa, Gdansk, Gdynia, Katowice

2026-02-24

Recruiting

Safety and Tolerability of IRL757 in Participants With Parkinson's Disease and Apathy

NCT07461220PARKINSON DISEASE (Disorder), Apathy, Safety

Integrative Research Laboratories AB

Phase 1/2

Bydgoszcz, Katowice, Lodz, Szczecin, Warsaw

2026-02-18

Recruiting

ShockFast Intravascular Lithotripsy Device for Treatment of Calcified Coronary Lesions

NCT07407738Coronary Arterial Disease, Calcified Coronary Artery Disease

Shunmei Medical

Not applicable

120

Katowice, Krakow, Lubin, Wroclaw

2026-02-16

Recruiting

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT07363694Moderate to Severe Chronic Obstructive Pulmonary Disease

Pfizer

Phase 2/3

1,156

Katowice, Krakow, Tarnów, Warsaw, Wroclaw, Ostrowiec Świętokrzyski

2026-02-11

Recruiting

A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis

NCT07250750Myasthenia Gravis

ImmunAbs Inc.

Phase 1/2

Katowice, Nowa Sól, Poznan, Zabrze

2026-02-05

Recruiting

Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia

NCT07284472Agitation Associated With Alzheimer's Disease Dementia

Exciva GmbH

Phase 2/3

300

Poznan, Krakow, Wroclaw, Lublin, Sochaczew, Warsaw, Katowice, Zabrze

2026-02-02

Recruiting

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

NCT07184944Crohn's Disease

DrugDuvakitug

Sanofi

Phase 3

751

Bydgoszcz, Elblag, Katowice, Kłodzko, Lublin, Rzeszów, Staszów, Szczecin

2026-01-22

Recruiting

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

NCT07277231Chronic Lymphocytic Leukemia

DrugsSonrotoclax·Acalabrutinib·Venclexta·Zanubrutinib

BeOne Medicines

Phase 3

500

Brzozów, Katowice, Krakow, Lublin, Wroclaw

2026-01-22

Recruiting

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

NCT07185009Ulcerative Colitis

DrugDuvakitug

Sanofi

Phase 3

751

Bydgoszcz, Elblag, Katowice, Krakow, Kłodzko, Lublin, Opole, Poznan

2026-01-16

Active, closed

A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis

NCT07223697Atopic Dermatitis

DrugAfimkibart

Hoffmann-La Roche

Phase 2

120

Katowice, Gdynia, Krakow, Rzeszów, Warsaw

2026-01-08

Recruiting

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)

DrugsPF-08634404·Pembrolizumab

Pfizer

Phase 3

1,410

Radom, Katowice, Kielce, Lodz, Lublin, Opole, Wroclaw, Tomaszów Mazowiecki

2026-01-06

Recruiting

A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa

NCT07384975Hidradenitis Suppurativa (HS)

Navigator Medicines, Inc.

Phase 2

150

Katowice, Kielce, Ossy, Warsaw, Wroclaw

2026-01-05

Active, closed

A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

NCT07277660Atopic Dermatitis

DrugGalvokimig

UCB Biopharma SRL

Phase 2

165

Chorzów, Katowice, Krakow, Lodz, Sosnowiec, Tarnów, Warsaw, Wroclaw

2025-12-29

Active, closed

Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

NCT07311850Obesity and Overweight

DrugBerobenatide

Pfizer

Phase 3

3,578

Bialystok, Bydgoszcz, Chojnice, Częstochowa, Gdansk, Gdynia, Katowice, Krakow

2025-12-19

Recruiting

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

NCT07284420AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG

DrugsEmpasiprubart·Efgartigimod

argenx

Phase 2

Bydgoszcz, Katowice, Warsaw

2025-12-19

Recruiting

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

NCT07294170Myasthenia Gravis, MG, gMG, Generalized Myasthenia Gravis

DrugsEmpasiprubart·Efgartigimod

argenx

Observational

Bydgoszcz, Krakow, Katowice, Warsaw

2025-12-19

Recruiting

A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression

NCT07300969Major Depressive Disorder (MDD)

DrugDT-101

Draig Therapeutics Ltd

Phase 2

300

Gdansk, Katowice, Poznan

2025-12-16

Recruiting

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

NCT07222800Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site

DrugsPF-08634404·Avastin·Bevacizumab

Pfizer

Phase 3

800

Katowice, Koszalin, Krakow, Opole, Poznan

2025-12-11

By invitation

RVU120 Rollover Study

NCT06987058Advanced Solid Tumors, Acute Myeloid Leukaemia (AML), High-risk Myelodysplastic Syndrome

DrugsRVU120·Ruxolitinib

Ryvu Therapeutics SA

Phase 2

Chorzów, Gdansk, Katowice, Krakow, Wroclaw

2025-12-04

Recruiting

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

NCT06937229Alzheimer Disease, Agitation

DrugsKarX-EC·KarXT

Bristol-Myers Squibb

Phase 3

650

Poznan, Bydgoszcz, Chorzów, Katowice, Krakow, Lublin, Sochaczew, Wroclaw

2025-12-02

Recruiting

A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

NCT06807281Atopic Dermatitis

DrugAbrocitinib

Pfizer

Phase 3

450

Lublin, Warsaw, Chorzów, Katowice, Lodz, Ostrowiec Świętokrzyski

2025-12-02

Recruiting

Comparing High and lOw-dose asPirin With Dual anTIplatelet Therapy for Three Months Using prasUgrel and aSpirin Following Coronary Artery Bypass Grafting. (OPTIMUS-CABG Trial)

NCT07195149Chronic Coronary Syndrome, Stable Coronary Artery Disease CAD

DrugsPrasugrel·Aspirin

Dolnośląskie Centrum Chorób Serca im.prof. Zbigniewa Religi MEDINET Sp. z o.o.

Phase 3

1,703

Bialystok, Bydgoszcz, Gdansk, Grudziądz, Katowice, Krakow, Lodz, Nowa Sól

2025-11-25

By invitation

Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

NCT07256392Chronic Spontaneous Urticaria

DrugBarzolvolimab

Celldex Therapeutics

Phase 3

1,370

Bialystok, Częstochowa, Elblag, Gdansk, Katowice, Krakow, Lublin, Oświęcim

2025-11-25

Recruiting

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

NCT07174310Parkinson's Disease

DrugPrasinezumab

Hoffmann-La Roche

Phase 3

900

Bia?ystok, Bydgoszcz, Gda?sk, Katowice, Krakow, Lublin, Oświęcim, Rzeszów

2025-11-24

Recruiting

A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema

NCT07216027Atopic Dermatitis, Eczema, Atopic

Pfizer

Phase 2

165

Krakow, Szczecin, Katowice

2025-11-20

Active, closed

Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

NCT07087054Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum

Crinetics Pharmaceuticals Inc.

Phase 3

141

Katowice, Warsaw, Wroclaw

2025-11-19

Recruiting

A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction

NCT07188805Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)

DrugFinerenone

Bayer

Phase 3

111

Wroclaw, Warsaw, Katowice, Lódz

2025-11-19

Recruiting

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

NCT07219420Palmoplantar Pustulosis

DrugBimekizumab

UCB Biopharma SRL

Phase 3

320

Bialystok, Gdansk, Katowice, Krakow, Lodz, Poznan, Rzeszów, Szczecin

2025-11-14

Recruiting

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo

NCT06804811NonSegmental Vitiligo

DrugRuxolitinib

Incyte Corporation

Phase 3

250

Gdansk, Katowice, Krakow, Lublin, Nowa Sól, Osielsko, Rzeszów, Szczecin

2025-11-13

Recruiting

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

NCT07225504Secondary Progressive Multiple Sclerosis (SPMS)

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

1,275

Krakow, Bydgoszcz, Chojnice, Katowice, Lodz, Lublin, Rzeszów, Skorzewo

2025-11-11

Recruiting

LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

NCT07186101Ulcerative Colitis

DrugsZotemtegrast·Mirikizumab

Eli Lilly and Company

Phase 2

252

Katowice, Piotrkow Trybunalski, Poznan, Szczecin, Warsaw, Zamość

2025-11-10

Active, closed

Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide

NCT07220642Obesity, Overweight

DrugCagrilintide

Novo Nordisk A/S

Phase 3

300

Bialystok, Katowice, Lublin, Warsaw

2025-11-05

Recruiting

A Study of Zasocitinib in Adults With Nonsegmental Vitiligo

NCT07108283Nonsegmental Vitiligo

DrugZasocitinib

Takeda

Phase 2

200

Osielsko, Wroclaw, Szczecin, Katowice, Rzeszów, Warsaw, Lodz, Kielce

2025-11-03

Active, closed

A Study With CIT-013 in HS Patients

NCT06993233Hidradenitis Suppurativa (HS)

Citryll BV

Phase 2

108

Bialystok, Gdansk, Katowice, Lodz, Poznan, Rzeszów, Wroclaw

2025-10-31

Recruiting

Single-stage Pulmonary Vein Isolation Combined With Percutaneous Left Atrial Appendage Occluder Implantation in Patients With Recent Onset Ischemic Stroke and Atrial Fibrillation

NCT06212674Ischemic Stroke, Atrial Fibrillation

DrugNOAC

Medical University of Silesia

Phase 4

240

Katowice, Zabrze

2025-10-31

By invitation

Clinical Trial of Vormatrigine in Adult Patients With Epilepsy

NCT07287163Epilepsy, Tonic-Clonic, Focal Seizure, Primary Generalized Seizure

Praxis Precision Medicines

Phase 3

700

Bydgoszcz, Katowice, Lublin, Warsaw

2025-10-27

Recruiting

A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A

NCT07220564Haemophilia A

Novo Nordisk A/S

Phase 1

Bialystok, Gdansk, Katowice, Lublin, Poznan, Warsaw

2025-10-23

Recruiting

Clinical Phase 2 Trial of AP31969 Versus Placebo for Rhythm Control of Atrial Fibrillation

NCT07267949Atrial Fibrillation (AF)

Acesion Pharma

Phase 2

200

Bydgoszcz, Chrzanów, Dąbrowa Górnicza, Katowice, Szczecin, Tychy

2025-10-22

Active, closed

A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis

NCT07260669Endometriosis

Gesynta Pharma AB

Phase 2

213

Bialystok, Bydgoszcz, Katowice, Krakow, Lublin, Siedlce, Skorzewo, Szczecin

2025-10-15

Recruiting

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

NCT07165028Metabolic Dysfunction-Associated Steatotic Liver Disease

DrugsRetatrutide·Tirzepatide

Eli Lilly and Company

Phase 3

4,500

Bialystok, Gdansk, Katowice, Lodz, Mysłowice, Poznan, Rzeszów, Warsaw

2025-10-15

Recruiting

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

NCT07221500Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)

DrugBexobrutideg

Nurix Therapeutics, Inc.

Phase 2

100

Katowice, Krakow, Skorzewo, Warsaw

2025-10-15

Recruiting

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

NCT07184996Ulcerative Colitis

DrugDuvakitug

Sanofi

Phase 3

980

Elblag, Katowice, Krakow, Lodz, Poznan, Rzeszów, Sopot, Staszów

2025-10-08

Recruiting

A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

NCT07023614Non-obstructive Hypertrophic Cardiomyopathy

Imbria Pharmaceuticals, Inc.

Phase 2

165

Katowice, Warsaw, Wroclaw

2025-10-06

Recruiting

Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes

NCT07102628Acute Coronary Syndrome

DrugInclisiran

Novartis Pharmaceuticals

Phase 3

300

Gdansk, Katowice, Krakow, Opole

2025-10-03

Recruiting

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

NCT07196748Colitis, Ulcerative

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

882

Bydgoszcz, Katowice, Krakow, Lublin, Nowy Targ, Olsztyn, Opole, Poznan

2025-10-01

Recruiting

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

NCT07184931Crohn's Disease

DrugDuvakitug

Sanofi

Phase 3

980

Bydgoszcz, Elblag, Katowice, Krakow, Kłodzko, Lodz, Lublin, Nowy Targ

2025-10-01

Not yet open

POPQ Associated With Total Laparoscopic Hysterectomy

NCT07137299Uterine Fibroids (UF), Abnormal Uterine Bleeding Unrelated to Menstrual Cycle, Endometrial Hyperplasia, Pelvic Organ Prolapse (POP)

Medical University of Silesia

Observational

2,000

Katowice, Warsaw

2025-10-01

Recruiting

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

NCT06979336Ulcerative Colitis

Genentech, Inc.

Phase 2

224

Bydgoszcz, Chojnice, Katowice, Knurów, Nowy Targ, Poznan, Skierniewice, Szczecin

2025-09-29

Active, closed

A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

NCT07169578Alzheimers Disease

DrugTrontinemab

Hoffmann-La Roche

Phase 3

1,101

Bydgoszcz, Katowice, Krakow, Lublin, Rzeszów, Warsaw, Wroc?aw, Zabrze

2025-09-17

Recruiting

A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

NCT07091630Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy

DrugEmpasiprubart

argenx

Phase 3

160

Katowice, Krakow, Warsaw

2025-09-16

Recruiting

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

NCT07190209Chronic Obstructive Pulmonary Disease

DrugLunsekimig

Sanofi

Phase 3

942

Wroclaw, Piaseczno, Bialystok, Katowice, Elblag, Sosnowiec

2025-09-16

Recruiting

Minimally Invasive Surgery Versus Open Radical Hysterectomy in Presumably Early Stage Cervical Cancer: a Retrospective Multicenter Non-inferiority Study Comparing Overall and Progression-free Survival.

NCT07120529Cervical Cancer, Hysterectomy

Medical University of Silesia

Observational

300

Bialystok, Katowice, Kielce, Opole, Wroclaw

2025-09-15

Recruiting

A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.

NCT07029828Severe Alopecia Areata

DrugsRitlecitinib higher·Ritlecitinib lower

Pfizer

Phase 3

140

Krakow, Wroclaw, Lublin, Warsaw, Katowice, Rzeszów, Lodz

2025-09-10

Recruiting

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)

Eli Lilly and Company

Phase 3

10,450

Bielsko-Biala, Bydgoszcz, Elblag, Grudziądz, Katowice, Komorniki, Krakow, Leszno

2025-09-02

Active, closed

A Study Evaluating TRIV-509 in Atopic Dermatitis

NCT07167758Atopic Dermatitis

Triveni Bio

Phase 2

Wroclaw, Warsaw, Chorzów, Katowice, Poznan, Sosnowiec

2025-08-26

Recruiting

Revascularization Strategies in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) and Severe Coronary Artery Disease

NCT01311323Multivessel Coronary Artery Disease, Acute Coronary Syndrome

American Heart of Poland

Not applicable

1,000

Chrzanów, Bielsko-Biala, Dąbrowa Górnicza, Ustroń, Katowice, Kędzierzyn-Koźle, Opole, Tychy

2025-08-25

Recruiting

A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

NCT06920004Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy

DrugsEmpasiprubart·IVIG

argenx

Phase 3

218

Bydgoszcz, Katowice, Krakow, Lublin, Poznan, Rzeszów, Szczecin, Warsaw

2025-08-22

Active, closed

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

NCT07018713Chronic Migraine

DrugXeomin

Merz Therapeutics GmbH

Phase 3

808

Bydgoszcz, Dębica, Gdynia, Katowice, Krakow, Lublin, Oświęcim, Poznan

2025-08-21

Active, closed

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine

NCT07018700Episodic Migraine

DrugXeomin

Merz Therapeutics GmbH

Phase 3

997

Bydgoszcz, Dębica, Gdynia, Katowice, Krakow, Lublin, Oświęcim, Poznan

2025-08-21

Active, closed

A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 Diabetes

NCT07112872Type 2 Diabetes Mellitus

DrugsRO7795081·Semaglutide

Hoffmann-La Roche

Phase 2

330

Bialystok, Gdansk, Bydgoszcz, Katowice, Lublin, Tarnów, Warsaw, Wroclaw

2025-08-19

Recruiting

A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

NCT06948318Immune Thrombocytopenic Purpura (ITP)

DrugMezagitamab

Takeda

Phase 3

150

Bydgoszcz, Warsaw, Katowice, Lodz

2025-08-14

Recruiting

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

NCT06774131Upper Urinary Tract Urothelial Carcinoma, Urothelial Carcinoma

UroGen Pharma Ltd.

Phase 3

Opole, Gdansk, Bydgoszcz, Katowice, Lublin, Olsztyn, Szczecin, Wroclaw

2025-08-06

Recruiting

DCB vs. DES in Bifurcation Coronary Lesions

NCT06551662Coronary Artery Disease, DCB

Fondazione Ricerca e Innovazione Cardiovascolare ETS

Not applicable

321

Gdansk, Katowice, Krakow, Lubin, Lublin, Poznan, Rzeszów, Warsaw

2025-08-01

Active, closed

A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata

NCT07029711Severe Alopecia Areata

DrugsRitlecitinib higher·Ritlecitinib lower

Pfizer

Phase 3

208

Krakow, Wroclaw, Lublin, Warsaw, Bialystok, Katowice, Ossy, Rzeszów

2025-07-31

Recruiting

A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia

NCT06721013Immune Thrombocytopenia (ITP)

DrugPirtobrutinib

Eli Lilly and Company

Phase 1/2

Katowice, Krakow, Skorzewo, Torun, Wroclaw

2025-07-30

Recruiting

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

NCT07037433Atherosclerotic Cardiovascular Disease, Overweight, Obesity

DrugMaridebart cafraglutide

Amgen

Phase 3

12,800

Bialystok, Bielsko-Biala, Bydgoszcz, Chojnice, Chrzanów, Dębica, Gdynia, Katowice

2025-07-25

Recruiting

A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema

NCT06807268Eczema

DrugAbrocitinib

Pfizer

Phase 3

150

Krakow, Lublin, Warsaw, Chorzów, Katowice, Lodz, Ostrowiec Świętokrzyski

2025-07-24

Recruiting

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

NCT07064473Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases

DrugsVicadrostat·Dapagliflozin

Boehringer Ingelheim

Phase 3

11,800

Bełchatów, Bialystok, Bydgoszcz, Chojnice, Częstochowa, Elblag, Gdynia, Katowice

2025-07-22

Recruiting

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

NCT06976203Alzheimer's Disease

DrugsKarX-EC·KarXT

Bristol-Myers Squibb

Phase 3

586

Oświęcim, Wroclaw, Lublin, Katowice

2025-07-21

Recruiting

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

NCT06943755Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)

DrugsZanzalintinib·Everolimus

Exelixis

Phase 2/3

440

Gliwice, Katowice, Krakow, Warsaw, Wroclaw

2025-07-21

Recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

NCT07011745Alzheimer's Disease

DrugsKarX-EC·KarXT

Bristol-Myers Squibb

Phase 3

426

Poznan, Bydgoszcz, Chorzów, Katowice, Krakow, Lublin, Sochaczew, Wroclaw

2025-07-16

Recruiting

A Phase 1b/2a Trial to Evaluate Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care.

NCT06832722Shock, Cardiogenic

4TEEN4 Pharmaceuticals GmbH

Phase 1/2

Bialystok, Katowice, Poznan, Wroclaw

2025-07-13

Active, closed

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)

NCT07076407Major Depressive Disorder

DrugAzetukalner

Xenon Pharmaceuticals Inc.

Phase 3

450

Bydgoszcz, Katowice, Poznan

2025-07-08

Active, closed

A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis

NCT06975722Ulcerative Colitis

DrugBrivekimig

Sanofi

Phase 2

105

Wroclaw, Bydgoszcz, Chojnice, Katowice, Sopot, Tychy, Warsaw

2025-07-07

Recruiting

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

NCT07177352Alzheimers Disease

Hoffmann-La Roche

Phase 3

80,000

?ory, ?ód?, B?dzin, Bia?ystok, Bydgoszcz, Gda?sk, Gdansk, Katowice

2025-07-02

Recruiting

Effects of High-Dose Vitamin D on Hormones, Neuromuscular Function, Cognition, and Body Composition in Athletes

NCT07641075Vitamin D 25-Hydroxylase Deficiency, Vitamin D Deficiency/Insufficiency

The Jerzy Kukuczka Academy of Physical Education in Katowice

Not applicable

200

Katowice

2025-07-01

Not yet open

Stereotactic Radiosurgery as Second-line Therapy for Ventricular Tachycardia

NCT07017855Ventricular Tachycardia, Monomorphic, Ventricular Tachycardia, Sustained, Ventricular Tachycardia (VT), Ventricular Tachycardia (V-Tach)

Medical University of Silesia

Not applicable

150

Katowice

2025-07-01

By invitation

Prehabilitation in Ovarian Cancer Patients During Chemiotherapy Before Cytoreductive Surgery.

NCT07058753Ovarian Cancer

Medical University of Silesia

Not applicable

100

Katowice

2025-07-01

Recruiting

A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults

NCT06937931Cervical Dystonia

DrugCorabotase

Ipsen

Phase 2

132

Katowice, Krakow, Oświęcim, Pabianice, Warsaw, Wroclaw

2025-06-30

Recruiting

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

NCT07082738Chronic Obstructive Pulmonary Disease (COPD)

AstraZeneca

Phase 2

987

Bialystok, Bydgoszcz, Chęciny, Elblag, Karczew, Katowice, Komorniki, Ksawerów

2025-06-27

By invitation

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa

NCT07007637Hidradenitis Suppurativa

DrugSonelokimab

MoonLake Immunotherapeutics AG

Phase 3

835

Bialystok, Chorzów, Gdansk, Katowice, Kielce, Krakow, Lodz, Lublin

2025-06-27

Recruiting

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

NCT06937086Ulcerative Colitis, Obesity or Overweight

DrugsMirikizumab·Tirzepatide

Eli Lilly and Company

Phase 3

350

Katowice, Opole, Piotrkow Trybunalski, Poznan, Rzeszów, Szczecin, Warsaw, Wroclaw

2025-06-26

Recruiting

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity

DrugMaridebart cafraglutide

Amgen

Phase 3

5,056

Bialystok, Bydgoszcz, Chrzanów, Elblag, Gdansk, Gdynia, Giżycko, Katowice

2025-06-25

Recruiting

INNODIA Family & Friends Early-Stage T1D Detection Protocol

NCT07118098Type 1 Diabetes (T1D), Pre Diabetes

INNODIA iVZW

Observational

30,000

Katowice

2025-06-25

Recruiting

Noradrenaline Versus Standard Blood Pressure Management for Perioperative Hypotension in Non-cardiac Surgery

NCT06885268Blood Pressure Management, Intraoperative Hypotension, Non-cardiac Surgery

Jagiellonian University

Phase 3

750

Katowice, Krakow, Olsztyn, Opole, Zabrze

2025-06-24

Active, closed

MEGA STUDY - Multicenter Evaluation of Gastroschisis Anomaly Study

NCT07030309Gastroschisis

ResearchSkills

Observational

200

Katowice, Poznan, Ruda Śląska, Rzeszów, Warsaw

2025-06-21

Recruiting

Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation

NCT06959095Pulmonary Disease, Chronic Obstructive

DrugDepemokimab

GlaxoSmithKline

Phase 3

981

Poznan, Katowice, Bialystok, Bydgoszcz, Krakow, Rzeszów, Wroclaw

2025-06-20

Recruiting

A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)

NCT06991257Heart Failure

DrugPF-07328948

Pfizer

Phase 2

620

Poznan, Bydgoszcz, Torun, Puławy, Sopot, Katowice

2025-06-19

Recruiting

A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

NCT07065240Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress

DrugGlyphAllo

Seaport Therapeutics

Phase 2

360

Bełchatów, Bialystok, Bydgoszcz, Gdansk, Katowice, Leszno, Poznan, Torun

2025-06-19

Active, closed

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

NCT06832618Atopic Dermatitis

DrugRuxolitinib

Incyte Corporation

Phase 3

159

Gdansk, Katowice, Krakow, Lodz, Lublin, Szczecin, Torun, Warsaw

2025-06-17

Active, closed

Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis

NCT06847724Relapsing Multiple Sclerosis

DrugOcrelizumab

Sandoz

Phase 3

183

Bydgoszcz, Katowice, Lodz, Lublin, Nowa Sól, Poznan, Szczecin, Warsaw

2025-06-10

Recruiting

A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

NCT06782490Multiple Sclerosis Spasticity

DrugIrafamdastat

Celgene

Phase 2

200

Bydgoszcz, Krakow, Oświęcim, Warsaw, Katowice, Gdansk, Słomniki, Lodz

2025-06-05

Recruiting

A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema

NCT06962839Macular Edema

Boehringer Ingelheim

Phase 2

300

Bielsko-Biala, Bydgoszcz, Katowice, Krakow, Olsztyn, Poznan, Tarnowskie Góry, Warsaw

2025-06-05

Recruiting

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

NCT07000357Cardiovascular Disease

DrugAZD0780

AstraZeneca

Phase 3

15,100

Bialystok, Bydgoszcz, Gdansk, Gdynia, Jelenia Góra, Katowice, Kędzierzyn-Koźle, Krakow

2025-06-04

Recruiting

Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis

NCT06850727Ulcerative Colitis (UC), UC - Ulcerative Colitis

DrugVedolizumab

Odyssey Therapeutics, Inc.

Phase 2

Bydgoszcz, Chojnice, Katowice, Rzeszów, Sopot, Staszów, Warsaw, Wroclaw

2025-06-02

Not yet open

Influence of Sensory Stimulation on Sensory Parameters and Motor Function in Children With Developmental Coordination Disorder

NCT06959329Developmental Coordination Disorder

The Jerzy Kukuczka Academy of Physical Education in Katowice

Not applicable

Katowice

2025-06-01

Not yet open

Oritavancin for CIED Infections With MDR Gram-positive Cocci

NCT07013552Cardiac Implantable Electronic Device Infections, Infective Endocarditis, Multidrug-resistant Bacteria Screening, Gram Positive Bacterial Infection

Medical University of Silesia

Not applicable

100

Katowice

2025-06

Active, closed

A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event

NCT07000123Cardiovascular Disease

DrugAZD0780

AstraZeneca

Phase 3

3,103

Bialystok, Gdansk, Gdynia, Katowice, Kędzierzyn-Koźle, Krakow, Lodz, Lublin

2025-05-28

Recruiting

A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

NCT07012395Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative

DrugsSPY001·SPY002·SPY003

Spyre Therapeutics, Inc.

Phase 2

645

Bydgoszcz, Katowice, Krakow, Opole, Poznan, Rzeszów, Sopot, Staszów

2025-05-27

Recruiting

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

NCT07039916Generalized Myasthenia Gravis

DrugIMVT-1402

Immunovant Sciences GmbH

Phase 3

231

Gdansk, Katowice, Krakow, Lublin, Warsaw

2025-05-27

Recruiting

Polish Registry of Percutaneous Coronary Intervention for Chronic Total Occlusions

NCT07330622Coronary Occlusion, Percutaneous Coronary Intervention

National Institute of Cardiology, Warsaw, Poland

Observational

1,000

Bialystok, Grodzisk Mazowiecki, Inowrocław, Katowice, Krakow, Lubin, Lublin, Nowy Sącz

2025-05-21

Recruiting

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

NCT06947993Atopic Dermatitis

Novartis Pharmaceuticals

Phase 2

224

Warsaw, Katowice, Lodz, Lublin

2025-05-16

Active, closed

Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense

NCT06993610Hidradenitis Suppurativa (HS)

Zura Bio Inc

Phase 2

247

Bialystok, Katowice, Malbork, Poznan, Szczecin, Warsaw

2025-05-16

Recruiting

Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis

NCT06909253Myasthenia Gravis, Generalized

DrugsUltomiris·Ravulizumab

AstraZeneca

Observational

Bydgoszcz, Gdansk, Katowice, Krakow, L DZ, Lublin, Poznan, Szczecin

2025-05-15

Recruiting

A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

NCT07003425Atopic Dermatitis

DrugAPG777

Apogee Therapeutics, Inc.

Phase 2

350

Wroclaw, Lublin, Warsaw, Gdansk, Katowice, Sosnowiec, Szczecin, Krakow

2025-05-14

Recruiting

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

NCT06925737Prostate Cancer, Prostatic Neoplasms

DrugsIfinatamab Deruxtecan·Prednisolone·Prednisone·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

1,440

Poznan, Bydgoszcz, Krakow, Siedlce, Warsaw, Katowice

2025-05-13

By invitation

Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study

NCT06914908Chronic Rhinosinusitis With Nasal Polyps

DrugsLunsekimig·Mometasone furoate

Sanofi

Phase 2

Poznan, Krakow, Wroclaw, Warsaw, Katowice

2025-05-12

Recruiting

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

NCT06499285Myelodysplastic Syndromes

DrugElritercept

Takeda

Phase 3

225

Poznan, Wroclaw, Katowice, Lodz, Olsztyn

2025-05-06

Recruiting

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

NCT06892548Advanced Lung Cancer

DrugsBNT324·Pumitamig

BioNTech SE

Phase 1/2

594

Gdansk, Katowice, Poznan

2025-05-02

By invitation

Normobaric Hypoxia as a Strength Training Intensity Amplifier in Ice Hockey Players: Effects on Anaerobic Performance and Muscle Contraction Properties

NCT06930027High-intensity Strenght Training in Normoxia (H-N), Low-intensity Strenght Training in Normoxia (L-N), High-intensity Strenght Training in Normobaric Hypoxia (H-H), Low-intensity Strenght Training in Normobaric Hypoxia (L-H)

The Jerzy Kukuczka Academy of Physical Education in Katowice

Not applicable

Katowice

2025-04-25

Recruiting

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

NCT06875310Carcinoma, Non-Small-Cell Lung

DrugsAdagrasib·Pemetrexed·Keytruda·Cisplatin

Mirati Therapeutics Inc.

Phase 3

630

Poznan, Gorlice, Krakow, Wroclaw, Lublin, Bydgoszcz, Katowice, Prabuty

2025-04-24

Active, closed

A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's

NCT06928142Sjogren Disease

DrugSibeprenlimab

Otsuka Pharmaceutical Development & Commercialization, Inc.

Phase 2

Poznan, Wroclaw, Siedlce, Warsaw, Wołomin, Bydgoszcz, Katowice, Lublin

2025-04-23

Recruiting

Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

NCT06966401Major Depressive Disorder

DrugOsavampator

Neurocrine Biosciences

Phase 3

850

Bełchatów, Bialystok, Bydgoszcz, Gdansk, Grudziądz, Katowice

2025-04-16

By invitation

The Impact of Omega-3 Fatty Acid Supplementation on the Composition of Erythrocyte Membranes

NCT07634133Healthy Volunteers

The Jerzy Kukuczka Academy of Physical Education in Katowice

Not applicable

200

Katowice

2025-04-15

Active, closed

A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

NCT06934226Plaque Psoriasis

DrugsIcotrokinra·Ustekinumab

Janssen Research & Development, LLC

Phase 3

752

Bialystok, Elblag, Katowice, Krakow, Lodz, Olsztyn, Poznan, Skierniewice

2025-04-15

Recruiting

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

NCT06890884Lymphoma, Large B-Cell, Diffuse

DrugsRituximab Biosimilar·Zilovertamab vedotin·Riabni·Ruxience

Merck Sharp & Dohme LLC

Phase 2

594

Skórzewo, Krakow, Nowy Sącz, Wałbrzych, Warsaw, Gdansk, Katowice

2025-04-11

Recruiting

A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

NCT06846671CLL, Chronic Lymphocytic Leukemia

DrugsIdelalisib·Tacabrutideg·Bendamustine·Venetoclax

BeOne Medicines

Phase 3

250

Brzozów, Katowice, Krakow, Lodz, Lublin, Wroclaw

2025-04-10

Active, closed

Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia

NCT06822790Hypertriglyceridemia

DrugPlozasiran

Arrowhead Pharmaceuticals

Phase 3

710

Elblag, Gdynia, Katowice, Krakow, Lodz, Malbork, Szczecin, Warsaw

2025-04-09

Recruiting

A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

NCT06873945Alopecia Areata

DrugsLitfulo·Ritlecitinib

Pfizer

Phase 3

674

Poznan, Krakow, Wroclaw, Lublin, Nowa Sól, Warsaw, Katowice, Sosnowiec

2025-04-01

Active, closed

A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis

NCT06863961Atopic Dermatitis

DrugAfimkibart

Hoffmann-La Roche

Phase 2

162

Gdynia, Katowice, Krakow, Rzeszów, Warsaw

2025-04-01

Active, closed

A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.

NCT06611163Moderate to Severe Genital Psoriasis

DrugTildrakizumab

Sun Pharmaceutical Industries Limited

Phase 3

206

Wroclaw, Lublin, Krakow, Rzeszw, Malbork, Bialystok-Podlaskie, Katowice, Warsaw

2025-03-21

Recruiting

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

NCT06883305Chronic Obstructive Pulmonary Disease (COPD)

DrugTezepelumab

AstraZeneca

Phase 3

990

Bialystok, Bydgoszcz, Chrzanów, Karczew, Katowice, Kielce, Krakow, Lodz

2025-03-18

Recruiting

Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT07032662Chronic Inflammatory Demyelinating Polyneuropathy

Immunovant Sciences GmbH

Phase 2

162

Lublin, Bydgoszcz, Gdansk, Katowice, Krakow, Poznan, Warsaw

2025-03-18

Active, closed

Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

NCT06858878Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight

DrugMaridebart cafraglutide

Amgen

Phase 3

1,105

Katowice, Lodz, Lublin, Oświęcim, Puławy, Ruda Śląska, Staszów, Świdnik

2025-03-17

Active, closed

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

NCT06764485Metastatic Castration-resistant Prostate Cancer

DrugsAbiraterone·Enzalutamide·Docetaxel

Celgene

Phase 3

960

Poznan, Wroclaw, Warsaw, Opole, Gdansk, Bytom, Bydgoszcz, Katowice

2025-03-13

Active, closed

Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

NCT06858839Obesity

DrugMaridebart cafraglutide

Amgen

Phase 3

3,853

Bialystok, Dębica, Gdynia, Katowice, Lodz, Lublin, Poznan, Warsaw

2025-03-12

Recruiting

Treatment of Presymptomatic (Stage 1) Type 1 Diabetes Pediatric Patients With Treg Cell Preparations and Anti-CD20 Antibody

NCT06688331Presymptomatic Diabetes Type 1 (Stage 1), Diabetes Mellitus, Type I, Diabetes Mellitus, Type 1

DrugRituximab

PolTREG S.A.

Phase 2

150

Bialystok, Gdansk, Katowice, Lodz, Lublin, Opole, Rzeszów, Szczecin

2025-03-12

Recruiting

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

NCT06615479Relapsed or Refractory Multiple Myeloma (RRMM)

DrugsArlo-cel·Carfilzomib·Pomalidomide·Daratumumab

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 3

440

Lublin, Gdansk, Katowice, Lodz

2025-03-12

Active, closed

HCL in Adults With T1DM, Markedly Elevated HbA1c, and Psychological Vulnerability

NCT07509060Type 1 Diabetes Mellitus

Jerzy Hohendorff

Not applicable

Katowice, Krakow, Poznan

2025-03-11

Recruiting

A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

NCT06641466Menstrual Migraine

DrugRimegepant

Pfizer

Phase 3

723

Krakow, Oświęcim, Wroclaw, Lublin, Warsaw, Katowice

2025-03-11

Recruiting

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

NCT06742723Chronic Kidney Disease and Hypertension

DrugBaxdrostat/dapagliflozin

AstraZeneca

Phase 3

5,000

Bialystok, Gdynia, Gmina Świecie, Jasło, Katowice, Krakow, Lodz, Lublin

2025-03-03

Recruiting

Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder

NCT06830044Major Depressive Disorder (MDD)

Vanda Pharmaceuticals

Phase 3

500

Bialystok, Bydgoszcz, Gdansk, Katowice, Suchy Las, Torun

2025-03-03

Recruiting

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

NCT06671483Psoriatic Arthritis

DrugZasocitinib

Takeda

Phase 3

1,088

Poznan, Krakow, Katowice, Sochaczew, Warsaw, Opole, Bialystok, Bytom

2025-03-03

Recruiting

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

NCT06855498Hidradenitis Suppurativa (HS)

DrugPovorcitinib

Incyte Corporation

Phase 3

600

Bialystok, Chorzów, Cracov, Gdansk, Gdynia, Grodzisk Mazowiecki, Katowice, Krakow

2025-02-28

Active, closed

Anifrolumab Real-world Treatment Outcomes in Systemic Lupus Erythematosus

NCT06673043Lupus Erythematosus, Systemic

DrugAnifrolumab

AstraZeneca

Observational

105

Bydgoszcz, Bytom, Gdansk, Katowice, Krakow, Lodz, Lublin, Poznan

2025-02-28

Recruiting

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

NCT06722235Immune Thrombocytopenic Purpura (ITP)

DrugMezagitamab

Takeda

Phase 3

171

Bydgoszcz, Warsaw, Katowice, Lodz

2025-02-27

Recruiting

UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies

NCT06590961Relapsed/Refractory B-cell Malignancies

Ubix Therapeutics, Inc.

Phase 1

Torun, Warsaw, Katowice, Grodzisk Wielkopolski

2025-02-20

Active, closed

Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

NCT06806293Menstrual Migraine (MM)

DrugAtogepant

AbbVie

Phase 3

468

Poznan, Bydgoszcz, Krakow, Oświęcim, Wroclaw, Katowice

2025-02-10

Active, closed

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

NCT06744920Generalized Myasthenia Gravis

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

180

Lublin, Krakow, Bydgoszcz, Katowice, Lodz, Poznan, Skorzewo, Warsaw

2025-02-07

Recruiting

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

NCT06712355Extensive-stage Small-cell Lung Cancer

DrugsPumitamig·Etoposide·Atezolizumab·Carboplatin

BioNTech SE

Phase 3

621

Gdansk, Katowice, Konin, Koszalin, Krakow, Lodz, Lublin, Olsztyn

2025-02-03

Recruiting

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma

DrugsFicerafusp alfa·Keytruda·Pembrolizumab

Bicara Therapeutics

Phase 2/3

650

Gdansk, Gliwice, Katowice, Konin, Krakow, Siedlce, Warsaw

2025-01-28

Recruiting

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

NCT06717347Diffuse Large B-Cell Lymphoma

DrugsRituximab Biosimilar·Zilovertamab vedotin·Riabni·Ruxience

Merck Sharp & Dohme LLC

Phase 3

1,046

Wroclaw, Lublin, Warsaw, Słupsk, Gliwice, Katowice, Olsztyn

2025-01-27

Recruiting

A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

NCT06680830Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD)

Neuron23 Inc.

Phase 2

150

Bydgoszcz, Katowice, Lublin, Warsaw

2025-01-17

Active, closed

A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome

NCT06684847Primary Sjogrens Disease

DrugEfgartigimod PH20

argenx

Phase 3

631

Bialystok, Bydgoszcz, Częstochowa, Elblag, Gdynia, Grodzisk Mazowiecki, Katowice, Krakow

2025-01-15

Active, closed

Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

NCT06700343Relapsing-remitting Multiple Sclerosis (RRMS)

DrugOcrelizumab

Amgen

Phase 3

152

Bydgoszcz, Katowice, Kielce, Krakow, Lodz, Lublin, Poznan, Warsaw

2025-01-13

Recruiting

A Prospective Observational Study of Video Laryngoscopy Versus Direct Laryngoscopy for Insertion of a Thin Endotracheal Catheter for Surfactant Administration in Newborn Infants

NCT06758492Respiratory Distress Syndrome (Neonatal), Respiratory Distress Syndrome (RDS), Video Laryngoscopy, Surfactant

University College Dublin

Observational

600

Gdansk, Katowice, Poznan, Rzeszów

2025-01-13

Recruiting

A Stepped Wedge Cluster Randomised Trial Of Video Versus Direct Laryngoscopy For Intubation Of Newborn Infants

NCT06757543Intubation, Intubation Complications, Infant, Newborn, Infant Respiratory Distress Syndrome

University College Dublin

Not applicable

840

Gdansk, Katowice, Rzeszów, Wroclaw

2025-01-13

Recruiting

The Impact of Omega-3 Fatty Acid Supplementation on the Composition of Erythrocyte Membranes in Athletes

NCT07768423Physical Performance, Cognitive Function, Sports Nutrition

The Jerzy Kukuczka Academy of Physical Education in Katowice

Not applicable

200

Katowice

2025-01-07

Recruiting

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

NCT06712316Non-small Cell Lung Cancer

DrugsPumitamig·Pemetrexed·Paclitaxel·Carboplatin

BioNTech SE

Phase 2/3

1,580

Bialystok, Bydgoszcz, Gdansk, Gliwice, Katowice, Kielce, Koszalin, Krakow

2025-01-07

Recruiting

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT06588478Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugPirtobrutinib

Loxo Oncology, Inc.

Phase 2

249

Bydgoszcz, Katowice, Krakow, Skórzewo, Wroclaw

2025-01-03

Recruiting

LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of Acquired Blepharoptosis.

NCT06514612Acquired Blepharophimosis

Santen SAS

Phase 3

234

Gdansk, Katowice, Warsaw

2024-12-30

Recruiting

RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures

NCT06798896Focal Onset Seizures

DrugSPN-817

Supernus Pharmaceuticals, Inc.

Phase 2

216

Krakow, Warsaw, Gdynia, Sopot, Katowice, Lublin

2024-12-30

Active, closed

A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)

NCT06687369Non Squamous Non Small Cell Lung Cancer

DrugsEU-sourced Keytruda·US-sourced Keytruda·Pemetrexed·Cisplatin

mAbxience Research S.L.

Phase 3

726

Katowice, Lodz, Lublin, Prabuty, Słupsk

2024-12-30

Active, closed

A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy

NCT06742190Multifocal Motor Neuropathy (MMN), MMN

DrugsEmpasiprubart·Immunoglobulin·IVIG

argenx

Phase 3

154

Bydgoszcz, Katowice, Krakow, Lublin, Warsaw

2024-12-18

Active, closed

A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies

NCT06645886Hematologic Malignancies, Adult

DrugsKQB198·Dasatinib

Kumquat Biosciences Inc.

Phase 1

Poznan, Gdansk, Katowice

2024-12-09

Active, closed

A Long-term Safety and Efficacy Study of N-Acetyl-GED-0507-34-LEVO Gel 5%, in Subjects With Acne Vulgaris (GEDACNE-LT)

NCT07389109Acne Vulgaris

PPM Services S.A.

Phase 3

400

Bialystok, Bydgoszcz, Chorzów, Częstochowa, Gdansk, Katowice, Krakow, Lodz

2024-12-05

Recruiting

MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)

NCT06534437Non-Hodgkin Lymphoma, B-cell

DrugGlofitamab

Ryvu Therapeutics SA

Phase 2

178

Biała Podlaska, Bydgoszcz, Gdansk, Gdynia, Gliwice, Katowice, Krakow, Olsztyn

2024-12-05

Recruiting

TES HT100 Clinical Validation for Brain Injury Screening in Patients With Mild Head Trauma or Neurological Symptoms

NCT07490418Mild Traumatic Brain Injury, Intracranial Lesions, Neurological Symptoms Not Related to Head Trauma

B&B srl

Not applicable

850

Gdansk, Katowice

2024-12-04

Recruiting

A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)

NCT06667700Coronavirus Disease (COVID-19)

DrugMolnupiravir

Merck Sharp & Dohme LLC

Phase 3

3,082

Poznan, Bydgoszcz, Krakow, Wroclaw, Warsaw, Gdynia, Bielsko-Biala, Katowice

2024-12-02

Recruiting

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

NCT06717698Chronic Kidney Disease

DrugSemaglutide

Novo Nordisk A/S

Phase 2

465

Włocławek, Lublin, Rzeszów, Bialystok, Gmina Świecie, Katowice, Lodz, Olsztyn

2024-12-02

Recruiting

Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

NCT06651281Crohn Disease, Colitis, Ulcerative

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 3

1,380

Poznan, Włocławek, Krakow, Wroclaw, Lublin, Warsaw, Katowice, Szczecin

2024-11-25

Recruiting

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

NCT06617325Systemic Lupus Erythematosus

UCB Biopharma SRL

Phase 3

450

Katowice, Krakow, Lublin, Poznan, Warsaw, Wroclaw

2024-11-21

By invitation

An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

NCT06435312Generalized Myasthenia Gravis

DrugZilucoplan

UCB Biopharma SRL

Phase 3

Katowice, Warsaw

2024-11-19

Active, closed

A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia

NCT06637501Chronic Lymphocytic Leukemia

DrugsSonrotoclax·Zanubrutinib

BeOne Medicines

Phase 2

Katowice, Krakow, Lublin, Wroclaw

2024-11-14

Recruiting

Use of Epoetin Alfa and Iron Derisomaltose in Treatment of Anemia in Patients With Sepsis or Septic Shock: a Randomized Controlled Trial

NCT06670963Anemia, Sepsis, Septic Shock

DrugsIron·NaCl

Piotr Czempik

Phase 4

200

Katowice

2024-11-10

Active, closed

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

NCT06676319Asthma

DrugsBudesonide/Formoterol·Lunsekimig

Sanofi

Phase 2

556

Poznan, Bialystok, Chęciny, Katowice, Ostrowiec Świętokrzyski

2024-11-07

Recruiting

A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

NCT06544499Primary Immune Thrombocytopenia (ITP)

DrugEfgartigimod

argenx

Phase 3

Bydgoszcz, Katowice, Lodz, Lublin, Nowy Sącz, Torun

2024-10-18

Recruiting

A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

NCT06055959Generalized Myasthenia Gravis

DrugZilucoplan

UCB Biopharma SRL

Phase 2/3

Katowice, Warsaw

2024-10-16

Active, closed

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response

NCT06641089Arthritis, Psoriatic

DrugsSonelokimab·Risankizumab

MoonLake Immunotherapeutics AG

Phase 3

600

Bialystok, Bydgoszcz, Częstochowa, Elblag, Gdynia, Katowice, Krakow, Lodz

2024-10-15

Active, closed

A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults

NCT06625060Episodic Migraine, Chronic Migraine

DrugCorabotase

Ipsen

Phase 2

670

Częstochowa, Katowice, Krakow, Lodz, Oświęcim, Pomorskie, Puławy, Siedlce

2024-10-10

Active, closed

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)

NCT06516965Prurigo Nodularis

DrugPovorcitinib

Incyte Corporation

Phase 3

346

Gdansk, Katowice, Lodz, Lublin, Poznan, Rzeszów, Torun, Warsaw

2024-10-10

Recruiting

Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis

NCT06619990Ulcerative Colitis (UC)

Xencor, Inc.

Phase 1/2

270

Bydgoszcz, Katowice, Krakow, Nowy Targ, Sopot, Staszów, Szczecin, Warsaw

2024-10-10

Active, closed

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)

NCT06516952Prurigo Nodularis

DrugPovorcitinib

Incyte Corporation

Phase 3

349

Bialystok, Gdansk, Katowice, Krakow, Lublin, Pruszków, Szczecin, Warsaw

2024-10-10

Recruiting

A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine

NCT06602479Migraine

AbbVie

Phase 2

488

Bydgoszcz, Katowice, Krakow, Lublin, Poznan, Warsaw

2024-10-07

Recruiting

LUMENS-1 EU EFS CIP

NCT06761365Aneurysm Cerebral, Bifurcation, Unruptured Intracranial Aneurysm, Saccular Aneurysm

LuSeed Vascular LTD.

Not applicable

Katowice, Lodz, Wroclaw

2024-10-07

Active, closed

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06417814Metastatic Non-small Cell Lung Cancer

DrugsTagrisso·Dato-DXd·Osimertinib·Pemetrexed

AstraZeneca

Phase 3

768

Katowice, Krakow, Lodz, Olsztyn, Poznan

2024-10-04

Recruiting

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

NCT06528314NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis

DrugEfruxifermin

Akero Therapeutics, Inc

Phase 3

2,150

Poznan, Krakow, Wroclaw, Lodz, Warsaw, Gdansk, Częstochowa, Katowice

2024-10-04

Recruiting

A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis

NCT06671054Rheumatoid Arthritis (RA)

DrugAP1189

SynAct Pharma Aps

Phase 2

240

Chorzów, Katowice, Poznan, Swidnica

2024-10-01

Recruiting

A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease

NCT06613698Liver Diseases, Alcoholic

DrugGSK4532990

GlaxoSmithKline

Phase 2

393

Katowice, Mysłowice, Warsaw

2024-09-27

Active, closed

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

NCT06238622Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis

DrugNerandomilast

Boehringer Ingelheim

Phase 3

1,666

Gdansk, Katowice, Świdnik, Warsaw

2024-09-26

Active, closed

To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications

NCT06553027Parkinson Disease

Cerevance

Phase 3

330

Lublin, Warsaw, Katowice

2024-09-20

Active, closed

A Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye Disease

NCT06557850Thyroid Eye Disease

H. Lundbeck A/S

Phase 1

Krakow, Katowice, Warsaw

2024-09-19

Active, closed

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis

NCT06558279Myasthenia Gravis, Ocular

argenx

Phase 3

141

Bydgoszcz, Katowice, Krakow, Lublin

2024-09-18

Active, closed

STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss

NCT06571383Obesity

DrugSemaglutide

Novo Nordisk A/S

Phase 4

500

Wroclaw, Gdansk, Katowice, Lodz, Rzeszów, Stanisławow Pierwszy Nieporet, Warsaw, Zabrze

2024-09-17

Active, closed

A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy

NCT06537999Multifocal Motor Neuropathy

DrugClaseprubart

Dianthus Therapeutics

Phase 2

Bydgoszcz, Katowice, Krakow

2024-09-17

Active, closed

RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms

NCT06243458Low Risk Myelodysplastic Syndromes

DrugRVU120

GCP-Service International West GmbH

Phase 2

Katowice, Lodz, Warsaw, Wroclaw

2024-09-10

Active, closed

Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome

NCT06315751Tourette Syndrome

Noema Pharma AG

Phase 2

164

Katowice

2024-09-10

Active, closed

Effect of Knee Mobilisation on Joint Position Sense and Tissues

NCT06540404Manual Therapy, Knee

The Jerzy Kukuczka Academy of Physical Education in Katowice

Not applicable

126

Katowice

2024-09-08

Active, closed

A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

NCT06550076Plaque Psoriasis

DrugZasocitinib

Takeda

Phase 3

2,099

Poznan, Krakow, Katowice, Kłodzko, Wroclaw, Lublin, Lódz, Nadarzyn

2024-09-04

Active, closed

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

NCT06486441Endometrial Cancer

DrugsAdriamycin·Sacituzumab Govitecan·Taxol·Doxorubicin

Gilead Sciences

Phase 3

640

Gdynia, Katowice, Poznan, Siedlce, Wroclaw

2024-08-28

Active, closed

A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)

NCT06564311Relapsing Multiple Sclerosis

DrugObexelimab

Zenas BioPharma (USA), LLC

Phase 2

Bydgoszcz, Katowice, Lublin, Zabrze

2024-08-26

Active, closed

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

NCT06461897Atopic Dermatitis

DrugsUpadacitinib·Dupilumab

AbbVie

Phase 3

699

Poznan, Torun, Krakow, Wroclaw, Warsaw, Bialystok, Katowice

2024-08-19

Recruiting

A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease

NCT06540833Psychotic Disorders, Alzheimer Disease

DrugITI-1284

Intra-Cellular Therapies, Inc.

Phase 2

370

Bydgoszcz, Katowice, Ścinawa

2024-08-15

Recruiting

EFS of the DUO System for Tricuspid Regurgitation

NCT05913908Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease, Heart Valve Diseases

CroiValve Limited

Not applicable

Poznan, Warsaw, Katowice, Lublin

2024-08-13

Recruiting

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

NCT06467357Biliary Tract Cancer

DrugsRilvegostomig·Trastuzumab deruxtecan·Durvalumab·Gemcitabine

AstraZeneca

Phase 3

620

Bialystok, Katowice, Krakow, Lublin, Warsaw, Wroclaw

2024-08-12

Active, closed

A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME

NCT06571045Diabetic Macular Edema (DME)

DrugsRemigromig·Lucentis·Ranibizumab

EyeBiotech Ltd.

Phase 2/3

984

Gdansk, Bialystok, Bydgoszcz, Katowice, Krakow, Olsztyn, Tarnowskie Góry

2024-08-07

Recruiting

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

NCT06549595Untreated Follicular Lymphoma

DrugsSurovatamig·R-Chop

AstraZeneca

Phase 3

1,018

Gdansk, Gliwice, Katowice, Krakow, Lublin, Warsaw, Wroclaw

2024-08-07

Recruiting

VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease

NCT06257706Moderately to Severely Active Crohn's Disease, Crohn Disease, Disease Crohn

DrugVedolizumab

Alimentiv Inc.

Phase 4

304

Łęczna, Poznan, Torun, Wroclaw, Warsaw, Rzeszów, Katowice, Szczecin

2024-08-07

Recruiting

Comparison of the Efficacy and Safety of Cardioneuroablation to Permanent Pacing in Patients With an Implanted Pacemaker for Symptomatic Bradycardia.

NCT05896592Bradycardia, Syncope

4th Military Clinical Hospital with Polyclinic, Poland

Not applicable

Radom, Katowice

2024-08-01

Active, closed

An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study

NCT06534892Respiratory Syncytial Virus Infections

DrugRSVPreF3 OA vaccine

GlaxoSmithKline

Phase 3

10,212

Częstochowa, Elblag, Gdansk, Gdynia, Katowice, Krakow, Lodz, Poznan

2024-08-01

Active, closed

A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.

NCT06517758Generalized Myasthenia Gravis

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

146

Lublin, Warsaw, Krakow, Katowice, Bydgoszcz, Poznan, Rzeszów

2024-07-31

Active, closed

A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy

NCT06440967Hot Flashes

DrugsFezolinetant·Tamoxifen

Astellas Pharma Global Development, Inc.

Phase 3

982

Poznan, Bialystok, Bydgoszcz, Katowice, Krakow, Lodz, Szczecin, Świdnik

2024-07-31

By invitation

Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus

NCT06475742Lupus Erythematosus, Systemic

DrugCenerimod

Viatris Innovation GmbH

Phase 3

680

Bydgoszcz, Częstochowa, Katowice, Poznan, Wroclaw

2024-07-30

Recruiting

Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

NCT06559306Depressive Disorder, Major

DrugSeltorexant

Janssen Research & Development, LLC

Phase 3

752

Bydgoszcz, Gdansk, Gorlice, Grudziądz, Katowice, Leszno, Poznan, Warsaw

2024-07-25

Active, closed

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)

NCT06355531Progressive Supranuclear Palsy

Ferrer Internacional S.A.

Phase 2

241

Katowice, Warsaw

2024-07-23

Active, closed

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)

NCT06455202Chronic Spontaneous Urticaria

DrugBarzolvolimab

Celldex Therapeutics

Phase 3

976

Częstochowa, Elblag, Gdansk, Grodzisk Mazowiecki, Katowice, Krakow, Lodz, Lublin

2024-07-19

Recruiting

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

NCT06226883Inflammatory Bowel Diseases, Crohn's Disease

DrugZotemtegrast

Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)

Phase 2

385

Bydgoszcz, Częstochowa, Elblag, Gdansk, Katowice, Krakow, Kłodzko, Opole

2024-07-18

Active, closed

A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

NCT06456580Generalized Myasthenia Gravis

DrugTelitacicept

Vor Biopharma

Phase 3

191

Poznan, Bydgoszcz, Krakow, Lublin, Nowa Sól, Warsaw, Gdansk, Katowice

2024-07-17

By invitation

A Randomised, Controlled, Double-blinded, Multi-country, Multi-centre Trial to Study Growth and Health Outcomes of a New Infant- and follow-on Formula for Healthy Term Infants.

NCT06475521Baby Formula, Growth Equivalence, Neurocognitive Development, Healthy Infants

Nutricia Research

Not applicable

579

Katowice

2024-07-17

Active, closed

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

NCT06456346Essential Thrombocythemia

DrugsBomedemstat·Hydroxyurea

Merck Sharp & Dohme LLC

Phase 3

300

Lublin, Katowice, Kielce

2024-07-16

Active, closed

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

NCT06445023Chronic Spontaneous Urticaria

DrugBarzolvolimab

Celldex Therapeutics

Phase 3

963

Bialystok, Bydgoszcz, Elblag, Gdansk, Katowice, Kielce, Krakow, Lodz

2024-07-11

Active, closed

A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus

NCT06015737Cutaneous Lupus Erythematosus

AstraZeneca

Phase 3

339

Katowice, Kielce, Ossy, Rzeszów, Warsaw

2024-06-29

Recruiting

A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis

NCT06392386Generalized Myasthenia Gravis

DrugEfgartigimod PH20

argenx

Phase 2/3

Gdansk, Katowice, Warsaw

2024-06-28

Active, closed

A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06468228Hidradenitis Suppurativa

DrugLutikizumab

AbbVie

Phase 3

1,400

Bydgoszcz, Krakow, Warsaw, Katowice, Lodz

2024-06-27

Active, closed

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma

NCT06356129Large B-cell Lymphoma

DrugsGolcadomide·Vincristine·Doxorubicin·Prednisone

Celgene

Phase 3

850

Skórzewo, Bydgoszcz, Krakow, Lublin, Warsaw, Katowice

2024-06-19

Recruiting

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

NCT06424288Heart Failure

DrugsVicadrostat·Dapagliflozin

Boehringer Ingelheim

Phase 3

6,712

Bialystok, Bydgoszcz, Chojnice, Częstochowa, Elblag, Gdansk, Gdynia, Katowice

2024-06-17

Active, closed

A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)

NCT06285643Parkinson Disease

DrugAAV2-GDNF gene therapy

AskBio Inc

Phase 2

127

Gdansk, Katowice, Warsaw

2024-06-11

Active, closed

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT06425991Multiple Myeloma

DrugTeclistamab

Janssen Research & Development, LLC

Phase 1

108

Biała Podlaska, Gdansk, Katowice, Kielce, Lublin, Wroclaw

2024-06-07

Recruiting

Bio Refine for Functional Mitral Regurgitation - a Safety & Feasibility Study

NCT06583876Functional Mitral Regurgitation

Bio Refine Ltd.

Not applicable

Katowice, Poznan, Warsaw

2024-06-03

Active, closed

A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

NCT06470438Lymphoma, Non-Hodgkin, Refractory B-Cell NHL, Relapsed B-cell NHL

Janssen Research & Development, LLC

Phase 1

Katowice, Kielce, Skorzewo

2024-05-28

Recruiting

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

NCT06419374Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis

DrugPegozafermin

Hoffmann-La Roche

Phase 3

1,800

Katowice, Krakow, Lodz, Mysłowice, Warsaw, Wroclaw

2024-05-24

Recruiting

VE303 for Prevention of Recurrent Clostridioides Difficile Infection

NCT06237452Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection

Vedanta Biosciences, Inc.

Phase 3

852

Warsaw, Katowice

2024-05-20

Recruiting

Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis

NCT06414954Myasthenia Gravis, Myasthenia Gravis, MuSK

NMD Pharma A/S

Phase 2

Katowice, Krakow, Lublin, Myślenice, Warsaw

2024-05-16

Active, closed

A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

NCT06407934Dermatitis Atopic

DrugAmlitelimab

Sanofi

Phase 3

1,541

Krakow, Tarnów, Lublin, Lodz, Warsaw, Gdansk, Katowice

2024-05-08

Active, closed

A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)

NCT06402838Alzheimer's Disease

Hoffmann-La Roche

Phase 2

256

?ory, Bia?ystok, Bydgoszcz, Katowice, Krakow, Sopot, Szczecin, Warsaw

2024-05-02

Active, closed

A Study Evaluating APG777 in Atopic Dermatitis

NCT06395948Atopic Dermatitis

DrugAPG777

Apogee Therapeutics, Inc.

Phase 2

470

Wroclaw, Lublin, Warsaw, Gdansk, Katowice, Sosnowiec, Szczecin, Krakow

2024-04-29

Recruiting

A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

NCT06338995Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

DrugLebrikizumab

Eli Lilly and Company

Phase 3

510

Bialystok, Katowice, Kielce, Krakow, Poznan, Warsaw, Wieliczka, Wroclaw

2024-04-29

Recruiting

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

NCT05485961End Stage Kidney Disease

DrugClazakizumab

CSL Behring

Phase 2/3

3,110

Brodnica, Katowice, Lodz, Naklo N. Notecią, Pszczyna, Stalowa Wola, Szczecin, Tczew

2024-04-27

Active, closed

A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

NCT06298552Generalized Myasthenia Gravis, gMG, Myasthenia Gravis, Generalized, Myasthenia Gravis

DrugEfgartigimod

argenx

Phase 3

119

Bydgoszcz, Katowice, Krakow, Lublin, Wroclaw

2024-04-16

Active, closed

A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis

DrugTeriflunomide

Sanofi

Phase 3

2,500

Plewiska, Bydgoszcz, Lublin, Lodz, Warsaw, Glogow Mlp., Katowice, Zabrze

2024-04-16

Active, closed

A Study of Barzolvolimab in Patients With Prurigo Nodularis

NCT06366750Prurigo Nodularis

DrugBarzolvolimab

Celldex Therapeutics

Phase 2

140

Krakow, Gdynia, Katowice, Lublin, Rzeszów, Warsaw, Wroclaw

2024-04-12

Recruiting

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

NCT06307652Heart Failure and Impaired Kidney Function

AstraZeneca

Phase 3

3,850

Biała Podlaska, Bielsko-Biala, Bydgoszcz, Chrzanów, Gdansk, Gdynia, Katowice, Kazimierza Wielka

2024-04-12

Active, closed

A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State

NCT06245408Sjögren's Syndrome (SS)

DrugDazodalibep

Amgen

Phase 3

434

Krakow, Wroclaw, Lublin, Warsaw, Wołomin, Malbork, Bydgoszcz, Katowice

2024-04-08

Recruiting

Reduction of Mitral Regurgitation With the SATURN Trans-Septal Transcatheter Mitral Valve Replacement (TMVR) System in Patients With Severe Symptomatic Mitral Regurgitation

NCT06414265Heart Failure

InnovHeart

Not applicable

Katowice, Warsaw

2024-04-04

Active, closed

Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)

NCT06180278Neuromyelitis Optica Spectrum Disorder

DrugsUplizna·Inebilizumab

Amgen

Phase 4

Warsaw, Katowice

2024-04-02

Active, closed

Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06290934Ulcerative Colitis

Gilead Sciences

Phase 2

228

Bydgoszcz, Katowice, Krakow, Ksawerów, Lublin, Mazowieckie, Poznan, Rzeszów

2024-03-27

Recruiting

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

NCT06256588Neoplasms, Head and Neck

DrugDostarlimab

GlaxoSmithKline

Phase 3

864

Bielsko-Biala, Gliwice, Katowice, Olsztyn, Przemyśl, Siedlce, Warsaw

2024-03-21

Active, closed

A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

NCT06132893Focal Epilepsy

DrugOpakalim

Biohaven Therapeutics Ltd.

Phase 2/3

390

Poznan, Lublin, Świdnik, Nowa Sól, Lodz, Warsaw, Gdansk, Katowice

2024-03-14

Recruiting

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis

DrugPegozafermin

Hoffmann-La Roche

Phase 3

1,350

Katowice, Krakow, Lodz, Mysłowice, Warsaw, Wroclaw

2024-03-13

Recruiting

The NEU-STIM Trial

NCT05942924Infant, Premature, Diseases, Birth, Preterm

Leiden University Medical Center

Not applicable

3,280

Bydgoszcz, Gdansk, Katowice, Poznan, Rzeszów, Wroclaw

2024-03-11

Active, closed

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

NCT06220604Plaque Psoriasis

DrugsIcotrokinra·Deucravacitinib

Janssen Research & Development, LLC

Phase 3

731

Bialystok, Katowice, Kielce, Krakow, Olsztyn, Warsaw, Wroclaw

2024-03-09

By invitation

The Influence of Modifying Highly Calcified Coronary Lesions on Coronary Microcirculation

NCT06507449Coronary Artery Calcification, Ischemic Heart Disease, Non-ST-Segment Elevation Myocardial Infarction (NSTEMI), Coronary Artery Disease

Medical University of Silesia

Not applicable

Katowice

2024-03-07

Active, closed

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

NCT06292013Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)

DrugLepodisiran

Eli Lilly and Company

Phase 3

17,300

Bialystok, Bydgoszcz, Chrzanów, Dąbrowa Górnicza, Elblag, Gdansk, Grudziądz, Katowice

2024-03-05

Active, closed

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

NCT06346392Gastric Cancer, Gastroesophageal Junction Cancer

DrugsSonesitatug Vedotin·Ramucirumab·Trifluridine/Tipiracil·Apatinib

AstraZeneca

Phase 3

594

Bielsko-Biala, Gdansk, Katowice, Krakow, Lublin, Słupsk, Warsaw

2024-03-04

Recruiting

Physiologic Cardiac Pacing to Prevent Left Ventricular Dysfunction Post TAVI

NCT05966675Atrioventricular Block, Second and Third Degree

Medical University of Silesia

Not applicable

500

Katowice

2024-02-27

Recruiting

Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.

NCT06239311Moderate to Severe Atopic Dermatitis

DrugMethotrexate

medac GmbH

Phase 3

277

Częstochowa, Gdansk, Katowice, Lodz, Lublin, Mikołów, Poznan, Szczecin

2024-02-27

Active, closed

A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)

NCT06282159Myasthenia Gravis, Generalized

DrugClaseprubart

Dianthus Therapeutics

Phase 2

Bydgoszcz, Katowice, Krakow, Lublin, Warsaw

2024-02-23

Recruiting

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

NCT06283966COPD (Chronic Obstructive Pulmonary Disease)

AstraZeneca

Phase 3

5,250

Bialystok, Bydgoszcz, Chęciny, Chojnice, Częstochowa, Inowrocław, Karczew, Katowice

2024-02-21

Recruiting

A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN, or LRP4

NCT06078553Congenital Myasthenic Syndrome

argenx

Observational

100

Bydgoszcz, Katowice, Warsaw

2024-02-13

Recruiting

Study of Olverembatinib (HQP1351) in Patients With CML-CP

NCT06423911Chronic Myeloid Leukemia, CML, CML, Chronic Phase

DrugsBosutinib·Olverembatinib

Ascentage Pharma Group Inc.

Phase 3

333

Gdansk, Katowice, Krakow, Lodz, Torun, Warsaw, Wałbrzych

2024-02-05

Recruiting

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

NCT06008197Heart Failure, Acute Heart Failure

DrugsKerendia·Finerenone

Colorado Prevention Center

Phase 3

5,200

Katowice, Krakow, Lodz, Lublin, Oświęcim, Tychy

2024-01-17

Recruiting

Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML

NCT06191263Acute Myeloid Leukemia

DrugsRVU120·Venetoclax

Ryvu Therapeutics SA

Phase 2

Warsaw, Biała Podlaska, Gdansk, Katowice, Torun, Wałbrzych, Wroclaw, Zielona Góra

2024-01-05

Recruiting

Multimodal Cardiac Imaging Registry in Patients with Atrial Fibrillation

NCT06584266Atrial Fibrillation and Flutter, Heart Failure, Artificial Intelligence (AI), Echocardiography

University in Zielona Góra

Observational

3,000

Nowa Sól, Katowice, Krakow, Warsaw, Zielona Góra

2024-01-01

Active, closed

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

NCT06079879Essential Thrombocythemia

DrugsAnagrelide·Bomedemstat·Busulfan·Ruxolitinib

Merck Sharp & Dohme LLC

Phase 3

340

Katowice, Kielce

2023-12-31

Recruiting

BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT

NCT06059638Hypertension, Hypertension, Systolic, Hypertension, Essential

Orchestra BioMed, Inc

Not applicable

316

Katowice, Krakow, Lodz, Lublin, Poznan, Szczecin, Warsaw, Wroclaw

2023-12-27

Active, closed

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

NCT06141486Multiple Sclerosis

DrugFrexalimab

Sanofi

Phase 3

943

Poznan, Bydgoszcz, Krakow, Rzeszów, Bialystok, Katowice, Zabrze

2023-12-27

Active, closed

A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo

NCT06118411Vitiligo

DrugUpadacitinib

AbbVie

Phase 3

614

Osielsko, Krakow, Warsaw, Bialystok, Katowice, Szczecin

2023-12-19

Recruiting

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

NCT06136559Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsNemtabrutinib·Ibrutinib·Acalabrutinib

Merck Sharp & Dohme LLC

Phase 3

1,200

Krakow, Lublin, Warsaw, Gdansk, Słupsk, Gliwice, Katowice, Olsztyn

2023-12-13

Active, closed

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

NCT06141473Multiple Sclerosis

DrugsCholestyramine·Activated Charcoal·Teriflunomide·Frexalimab

Sanofi

Phase 3

1,655

Plewiska, Bydgoszcz, Krakow, Lublin, Lodz, Warsaw, Rzeszów, Katowice

2023-12-13

Recruiting

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

NCT06091254Follicular Lymphoma (FL)

DrugsOdronextamab·Prednisone/Prednisolone·Adriamycin·Bendamustine

Regeneron Pharmaceuticals

Phase 3

822

Wałbrzych, Wroclaw, Krakow, Gdansk, Skorzewo, Katowice, Lodz, Lublin

2023-12-12

Active, closed

Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS)

NCT06111586Type 1 Diabetes Mellitus

DrugFrexalimab

Sanofi

Phase 2

197

Lodz, Warsaw, Bialystok, Katowice, Szczecin

2023-12-11

Active, closed

Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women With Recurrent Vulvovaginal Candidiasis: A Randomized Controlled Study

NCT06190509Recurrent Vulvovaginal Candidiasis

LimmaTech Biologics AG

Phase 1/2

251

Skórzewo, Bydgoszcz, Katowice, Lublin, Warsaw

2023-12-06

Active, closed

A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients

NCT06514807Essential Thrombocythaemia

DrugBesremi

AOP Orphan Pharmaceuticals AG

Phase 3

117

Gdansk, Katowice, Krakow, Lodz

2023-12-04

Active, closed

A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)

NCT06127043Ulcerative Colitis

DrugRosnilimab

AnaptysBio, Inc.

Phase 2

132

Bydgoszcz, Częstochowa, Elblag, Katowice, Krakow, Lodz, Lublin, Poznan

2023-12-04

Recruiting

Remote ECG Monitoring Post TAVI

NCT07521800TAVI(Transcatheter Aortic Valve Implantation), Remote Monitoring, Arrythmia, Atrial Fibrillation (AF)

Medical University of Silesia

Not applicable

250

Bialystok, Katowice

2023-12-01

Recruiting

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

NCT06215716NASH With Fibrosis, MASH With Fibrosis

DrugEfruxifermin

Akero Therapeutics, Inc

Phase 3

1,650

Poznan, Krakow, Wroclaw, Warsaw, Gdansk, Gdynia, Częstochowa, Katowice

2023-12-01

Active, closed

A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)

NCT06113445NonSegmental Vitiligo

DrugPovorcitinib

Incyte Corporation

Phase 3

467

Chorzów, Częstochowa, Gdansk, Katowice, Lodz, Osielsko, Ostrowiec Świętokrzyski, Rzeszów

2023-11-29

Active, closed

A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy

NCT05988073Multifocal Motor Neuropathy

argenx

Observational

413

Bydgoszcz, Katowice, Krakow, Lublin, Warsaw

2023-11-29

Active, closed

A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)

NCT06113471NonSegmental Vitiligo

DrugPovorcitinib

Incyte Corporation

Phase 3

450

Gdansk, Gdynia, Katowice, Kielce, Lodz, Skierniewice, Szczecin, Tarnów

2023-11-27

Recruiting

A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts

NCT06094010Influenza

DrugBaloxavir Marboxil

Hoffmann-La Roche

Phase 3

1,100

Bydgoszcz, Częstochowa, Grójec, Katowice, Lodz, Siemianowice Śląskie, Warsaw, Wo?omin

2023-11-22

Active, closed

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis

NCT06136741Moderate to Severe Atopic Dermatitis

DrugRezpegaldesleukin

Nektar Therapeutics

Phase 2

396

Wroclaw, Warsaw, Rzeszów, Gdansk, Gdynia, Częstochowa, Iława, Katowice

2023-11-15

Active, closed

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

NCT06062420Neoplasms, Head and Neck

DrugsRemzistotug·Nelistotug·Belrestotug·Dostarlimab

GlaxoSmithKline

Phase 2

316

Bielsko-Biala, Katowice, Krakow, Przemyśl, Siedlce, Warsaw

2023-11-14

Active, closed

A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma

NCT06097364Follicular Lymphoma (FL)

DrugsOdronextamab·Prednisone/Prednisolone·Adriamycin·Cytoxan

Regeneron Pharmaceuticals

Phase 3

733

Krakow, Skorzewo, Bydgoszcz, Gdansk, Katowice, Lodz, Lublin, Warsaw

2023-11-14

Active, closed

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

NCT06072183Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo

DrugRitlecitinib

Pfizer

Phase 3

1,571

Bydgoszcz, Krakow, Warsaw, Bialystok, Katowice, Szczecin, Lodz

2023-11-08

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

NCT06025578Progressive Pulmonary Fibrosis

DrugAdmilparant

Bristol-Myers Squibb

Phase 3

1,057

Bydgoszcz, Krakow, Bialystok, Gdansk, Olsztyn, Będzin, Katowice, Lodz

2023-10-25

Active, closed

ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions

NCT05949684Myelodysplastic Syndromes

DrugsEpoetin Alfa·Reblozyl·Luspatercept

Bristol-Myers Squibb

Phase 3

402

Wałbrzych, Gdansk, Katowice, Warsaw

2023-10-24

Active, closed

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults

NCT06047444Chronic Migraine

DrugsDysport·Botulinum toxin type A

Ipsen

Phase 3

759

Bydgoszcz, Gdynia, Katowice, Krakow, Lublin, Oświęcim

2023-10-12

Recruiting

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

NCT06012240Alopecia Areata

DrugUpadacitinib

AbbVie

Phase 3

1,500

Osielsko, Torun, Krakow, Wroclaw, Warsaw, Bialystok, Katowice, Elblag

2023-10-11

Active, closed

A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants

NCT06045689Myelodysplastic Syndromes

DrugsReblozyl·Luspatercept

Bristol-Myers Squibb

Phase 3

106

Lódz, Warsaw, Katowice, Wałbrzych

2023-10-05

Active, closed

A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults

NCT06047457Episodic Migraine

DrugsDysport·Botulinum toxin type A

Ipsen

Phase 3

751

Bydgoszcz, Gdynia, Katowice, Krakow, Lublin, Oświęcim

2023-09-29

Recruiting

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT05730036Relapsed Refractory Multiple Myeloma (RRMM)

DrugsElotuzumab·Linvoseltamab·Pomalidomide·Dexamethasone

Regeneron Pharmaceuticals

Phase 3

410

Gdansk, Bydgoszcz, Katowice, Lublin, Lodz

2023-09-18

Active, closed

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

NCT06047080Large B-Cell Lymphoma

DrugsPolatuzumab Vedotin·Glofitamab·Doxorubicin·Prednisone

Hoffmann-La Roche

Phase 3

1,130

Brzozów, Gda?sk, Katowice, Kielce, Krakow, Wroc?aw

2023-09-18

Recruiting

The ReTAVI Prospective Observational Registry

NCT05601453Structural Valve Deterioration, Structural Valve Degeneration, Symptomatic Patients Who Have Had Transcatheter Heart Valve (THV) Failure, Prosthetic Valve Malfunction

Institut für Pharmakologie und Präventive Medizin

Observational

250

Bialystok, Gdansk, Katowice, Krakow, Warsaw, Wroclaw

2023-09-05

Active, closed

A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

NCT06081894Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

DrugAficamten

Cytokinetics

Phase 3

500

Katowice

2023-08-31

Recruiting

A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis

NCT06016842Primary Biliary Cholangitis (PBC)

DrugElafibranor

Ipsen

Phase 3

276

Elblag, Katowice, Krakow, Lodz, Lublin, Małogoskie, Rzeszów, Sosnowiec

2023-08-31

Recruiting

A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)

NCT06064890Frontotemporal Dementia, FTD, FTD-GRN, Dementia, Frontotemporal

AviadoBio Ltd

Phase 1/2

Katowice, Szczecin, Warsaw

2023-08-30

Recruiting

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

NCT06126224Psychosis Associated With Alzheimer's Disease

DrugKarXT

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

500

Lublin, Lodz, Sopot, Katowice, Bydgoszcz, Siemianowice Śląskie, Ścinawa

2023-08-28

Active, closed

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

NCT05995964Atopic Dermatitis

DrugTilrekimig

Pfizer

Phase 2

507

Poznan, Krakow, Wroclaw, Katowice, Ostrowiec Świętokrzyski

2023-08-22

Active, closed

A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder

NCT06021522Tourette Syndrome

Emalex Biosciences Inc.

Phase 3

150

Katowice, Gdansk, Poznan, Krakow

2023-08-16

Active, closed

A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies

NCT05885555Primary Immune Thrombocytopenia (ITP)

DrugIanalumab

Novartis Pharmaceuticals

Phase 2

Katowice

2023-08-16

Active, closed

Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension

NCT05968430Hypertension

Mineralys Therapeutics Inc.

Phase 3

1,076

Katowice, Lodz, Olsztyn, Skierniewice, Warsaw

2023-07-14

Recruiting

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

NCT05980949Psychosis Associated With Alzheimer's Disease

DrugKarXT

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

1,000

Poznan, Lodz, Lódz, Gdansk, Iława, Bydgoszcz, Katowice, Kielce

2023-07-11

Active, closed

Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy

NCT05696717Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy

Theravance Biopharma

Phase 3

102

Gdansk, Katowice, Krakow, Oświęcim

2023-06-27

Active, closed

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

NCT05827016Multiple Myeloma

DrugsIberdomide·Lenalidomide

Bristol-Myers Squibb

Phase 3

1,230

Bydgoszcz, Gdansk, Gliwice, Katowice, Lublin, Warsaw, Lodz

2023-06-22

Recruiting

The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)

NCT05427370Coronary Artery Disease, Heart Failure Systolic

Sunnybrook Health Sciences Centre

Not applicable

754

Bialystok, Katowice

2023-06-22

Recruiting

Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

NCT05877963Relapsing Multiple Sclerosis

DrugUblituximab

TG Therapeutics, Inc.

Phase 3

800

Bydgoszcz, Katowice, Kielce, Krakow, Lodz, Olsztyn, Poznan, Warsaw

2023-06-13

Recruiting

A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

NCT05442567Ulcerative Colitis, Crohn's Disease

DrugVedolizumab

Takeda

Phase 3

240

Krakow, Wroclaw, Warsaw, Rzeszów, Gdansk, Katowice, Szczecin, Lodz

2023-05-16

Recruiting

Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women

NCT04124120Heart Diseases, Coronary Artery Disease, Coronary Artery Bypass Grafting

Weill Medical College of Cornell University

Not applicable

2,300

Gdansk, Katowice, Zabrze

2023-04-17

Recruiting

Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2

NCT05555589Neurotrophic Keratopathy

ReGenTree, LLC

Phase 3

Katowice

2023-04-11

Active, closed

A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis

NCT05785611Axial Spondyloarthritis

DrugFilgotinib

Alfasigma S.p.A.

Phase 3

495

Bialystok, Elblag, Katowice, Lubin, Lublin, Nowa Sól, Olsztyn, Opole

2023-04-05

Active, closed

Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

NCT05769777Dermatitis Atopic

DrugAmlitelimab

Sanofi

Phase 2

999

Lublin, Lodz, Warsaw, Gdansk, Chorzów, Katowice

2023-04-03

Active, closed

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

NCT05572515Relapsed or Refractory Multiple Myeloma

DrugsTeclistamab·Carfilzomib·Pomalidomide·Bortezomib

Janssen Research & Development, LLC

Phase 3

614

Gdansk, Katowice, Kielce, Lublin

2023-03-29

Active, closed

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

NCT05624554Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsNemtabrutinib·Riabni·Ruxience·Truxima

Merck Sharp & Dohme LLC

Phase 3

300

Lublin, Warsaw, Gdansk, Katowice, Olsztyn, Kielce

2023-03-16

Recruiting

A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

NCT05723198Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases

DrugBaricitinib

Eli Lilly and Company

Phase 3

595

Gdansk, Katowice, Kielce, Krakow, Lodz, Rzeszów, Swietokrzyski, Warsaw

2023-02-27

Active, closed

Study With Various Immunotherapy Treatments in Participants With Lung Cancer

NCT05676931Advanced Non-Small Cell Lung Cancer

DrugsQuemliclustat·Domvanalimab·Zimberelimab·Docetaxel

Gilead Sciences

Phase 2

400

Gdynia, Katowice, Poznan, Warsaw

2023-02-21

Active, closed

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

NCT05702034Ischemic Stroke; Ischemic Attack, Transient

DrugMilvexian

Janssen Research & Development, LLC

Phase 3

12,523

Bialystok, Bolesławiec, Bydgoszcz, Chelmie, Działdowo, Grodzisk Mazowiecki, Gryfice, Katowice

2023-02-15

Recruiting

A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

NCT05667142Primary Generalized Tonic-Clonic Seizures

DrugAzetukalner

Xenon Pharmaceuticals Inc.

Phase 3

160

Bydgoszcz, Gdansk, Katowice, Lublin, Nowa Sól

2023-02-14

Recruiting

Clinical Value and Cost-effectiveness of a Personalized Prevention Program (PPP) in Patients With High Risk Stable CHD

NCT04433052Coronary Heart Disease

Tampere University

Not applicable

12,000

Bialystok, Katowice, Krakow, Lublin, Toruniak, Warsaw

2023-02-01

Active, closed

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma

NCT05748600Eosinophilic Asthma, Asthma; Eosinophilic, Asthma Attack

DrugDexpramipexole Dihydrochloride

Areteia Therapeutics

Phase 3

600

Będzin, Bialystok, Gdansk, Giżycko, Katowice, Krakow, Lodz, Lublin

2023-01-30

Active, closed

Study to Assess SLN124 in Patients With Polycythemia Vera

NCT05499013Polycythemia Vera

Silence Therapeutics plc

Phase 1/2

Gdansk, Katowice, Lublin

2023-01-26

Active, closed

A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

NCT05617677Systemic Lupus Erythematosus

DrugDeucravacitinib

Bristol-Myers Squibb

Phase 3

516

Poznan, Bydgoszcz, Krakow, Nadarzyn, Warsaw, Katowice, Bialystok, Lublin

2023-01-12

Active, closed

A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease

NCT05668013Crohn Disease, Colitis, Ulcerative

DrugDuvakitug

Teva Branded Pharmaceutical Products R&D LLC

Phase 2

247

Bydgoszcz, Częstochowa, Elblag, Gdansk, Katowice, Krakow, Kłodzko, Lodz

2023-01-11

Recruiting

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

NCT05712200Atrial Fibrillation (AF)

DrugAbelacimab

Anthos Therapeutics, Inc.

Phase 3

2,500

Bialystok, Czeladź, Elblag, Gdynia, Katowice, Krakow, Legnica, Lodz

2022-12-27

Active, closed

Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)

NCT05531526Alzheimer Disease

AriBio Co., Ltd.

Phase 3

1,535

Bialystok, Katowice, Ścinawa, Warsaw, Wroclaw

2022-12-23

Recruiting

A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

NCT05287126Ulcerative Colitis

DrugEtrasimod

Pfizer

Phase 2

Warsaw, Katowice, Krakow, Szczecin, Wroclaw

2022-12-16

Active, closed

CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

NCT05681351Severe Hypertriglyceridemia

DrugOlezarsen

Ionis Pharmaceuticals, Inc.

Phase 3

885

Gdansk, Józefów, Katowice, Lodz, Lublin, Poznan, Tarnów, Warsaw

2022-12-13

Active, closed

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

NCT05648500Lupus Erythematosus, Systemic

DrugCenerimod

Viatris Innovation GmbH

Phase 3

470

Bialystok, Częstochowa, Katowice, Krakow, Lublin, Wroclaw

2022-12-13

Active, closed

Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis

NCT05588843Colitis Ulcerative

Sanofi

Phase 2

187

Włocławek, Wroclaw, Łęczna, Warsaw, Gdynia, Katowice, Tychy, Krakow

2022-11-25

Active, closed

Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

NCT05556096Generalized Myasthenia Gravis

Alexion Pharmaceuticals, Inc.

Phase 3

260

Bydgoszcz, Katowice, Krakow, Lublin, Poznan

2022-11-21

Recruiting

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

NCT05623020Multiple Myeloma

DrugsElranatamab·Bortezomib·Daratumumab·Lenalidomide

Pfizer

Phase 3

1,060

Wroclaw, Gdansk, Katowice

2022-11-10

Active, closed

A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)

NCT05490446Myelodysplastic Syndromes

DrugTebapivat

Agios Pharmaceuticals, Inc.

Phase 2

Warsaw, Katowice, Olsztyn

2022-11-07

Active, closed

Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

NCT05397639Agitation, Alzheimer's Type Dementia

Suven Life Sciences Limited

Phase 3

375

Lodz, Warsaw, Katowice, Zabrze

2022-11-01

Active, closed

A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

NCT05567796Obesity

DrugsCagrilintide·Semaglutide

Novo Nordisk A/S

Phase 3

3,400

Bydgoszcz, Krakow, Legnica, Lublin, Warsaw, Bialystok, Gdansk, Katowice

2022-11-01

Recruiting

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

NCT05552222Multiple Myeloma

DrugsTalquetamab·Teclistamab·Daratumumab·Lenalidomide

Janssen Research & Development, LLC

Phase 3

1,590

Biała Podlaska, Brzozów, Bydgoszcz, Katowice, Kielce, Lodz, Lublin, Poznan

2022-10-25

Active, closed

A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer

NCT05587296Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer, Hot Flashes

Bayer

Phase 3

474

Bialystok, Katowice, Krakow, Lodz, Skorzewo, Warsaw

2022-10-14

Active, closed

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

NCT05455320Multiple Myeloma

DrugsTalquetamab·Pomalidomide·Daratumumab·Dexamethasone

Janssen Research & Development, LLC

Phase 3

864

Brzozów, Gdansk, Katowice, Kielce, Krakow, Lublin, Olsztyn, Szczecin

2022-10-13

Active, closed

Efficacy and Safety of AC102 Compared to Steroids in Adults With Idiopathic Sudden Sensorineural Hearing Loss (ISSNHL)

NCT05776459Hearing Loss, Sensorineural

DrugPrednisolone

AudioCure Pharma GmbH

Phase 2

210

Bydgoszcz, Katowice, Lodz, Opole, Rzeszów, Szczecin, Warsaw

2022-10-13

Active, closed

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

NCT05508789Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases

DrugDonanemab

Eli Lilly and Company

Phase 3

1,500

Bialystok, Bydgoszcz, Gdansk, Katowice, Krakow, Poznan, Szczecin, Warsaw

2022-10-10

Recruiting

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT05519085Relapsed or Refractory Multiple Myeloma

DrugsMezigdomide·Velcade·Pomalidomide·Bortezomib

Celgene

Phase 3

810

Skórzewo, Torun, Krakow, Warsaw, Słupsk, Katowice

2022-09-20

Active, closed

A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT05057494Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

DrugsAcalabrutinib·Obinutuzumab·Venetoclax

AstraZeneca

Phase 3

607

Bydgoszcz, Gdansk, Katowice, Krakow, Lódz, Lublin

2022-09-12

Recruiting

Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV)

NCT06506084Polycythemia Vera

DrugBesremi

FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS

Observational

429

Gdansk, Katowice, Krakow, Lodz, Wroclaw

2022-09-08

Recruiting

Asciminib Roll-over Study

NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

DrugsAsciminib single agent·Bosutinib·ABL001·Nilotinib

Novartis Pharmaceuticals

Phase 4

347

Katowice, Krakow, Warsaw, Wroclaw

2022-08-30

Active, closed

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease

NCT05271409Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

DrugSatralizumab

Hoffmann-La Roche

Phase 3

139

Katowice, Warsaw, Zabrze

2022-08-30

Active, closed

A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

NCT05399888Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia

Biogen

Phase 2

416

Bialystok, Bydgoszcz, Katowice, Krakow, Lodz, Lublin, Sopot, Warsaw

2022-08-24

By invitation

Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis

NCT05374590Generalized Myasthenia Gravis, gMG

DrugsEfgartigimod PH20·Efgartigimod

argenx

Phase 2/3

Gdansk, Katowice, Warsaw

2022-08-18

Recruiting

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

NCT05489705Obstructive Hypertrophic Cardiomyopathy

DrugMavacamten

Bristol-Myers Squibb

Observational

1,700

Katowice, Warsaw

2022-08-16

Active, closed

A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow

NCT05330325SGA, Turner Syndrome, Noonan Syndrome, ISS

DrugsNorditropin·Somapacitan

Novo Nordisk A/S

Phase 3

412

Rzeszów, Cracow, Gdansk, Katowice, Lodz, Szczecin, Zabrze

2022-08-10

Active, closed

Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis

NCT05297448Hepatic Encephalopathy

DrugRifaximin SSD

Bausch Health Americas, Inc.

Phase 3

466

Bydgoszcz, Katowice, Krakow, Mysłowice, Staszów, Wroclaw

2022-08-03

Recruiting

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT05254743Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma

DrugsPirtobrutinib·Ibrutinib

Loxo Oncology, Inc.

Phase 3

737

Biała Podlaska, Bydgoszcz, Gdansk, Katowice, Krakow, Lublin, Skórzewo, Wroclaw

2022-07-22

Active, closed

A Feasibility Study of the CroíValve DUO System for Tricuspid Regurgitation

NCT05296148Tricuspid Regurgitation

CroiValve Limited

Not applicable

Gdansk, Katowice, Warsaw

2022-06-17

Recruiting

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

NCT05429632Adult Acute Myeloid Leukemia

Priothera SAS

Phase 3

366

Krakow, Katowice, Gdansk, Warsaw

2022-06-16

Active, closed

Ivabradine for Prevention of Myocardial Injury After Noncardiac Surgery Trial (PREVENT-MINS)

NCT05279651Myocardial Injury After Noncardiac Surgery (MINS), Myocardial Ischemia

DrugIvabradine

Jagiellonian University

Phase 3

2,146

Bydgoszcz, Ciechanów, Cieszyn, Gdansk, Gmina Końskie, Katowice, Krakow, Lodz

2022-06-13

Recruiting

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

NCT05280509Myelofibrosis, Primary Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis

DrugsJakavi·Ruxolitinib

Telios Pharma, Inc.

Phase 1/2

Katowice

2022-06-09

Recruiting

A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option

NCT05179876Hypertension, Pulmonary

DrugsMacitentan·Selexipag

Actelion

Phase 3

280

Bialystok, Bydgoszcz, Katowice, Lodz, Lublin, Szczecin, Wroclaw

2022-05-04

Active, closed

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

NCT05269004Multiple Sclerosis

DrugOcrelizumab

Hoffmann-La Roche

Phase 3

1,300

Bydgoszcz, Gda?sk, Katowice, Krakow, Lodz, Lublin, Olsztyn, Plewiska

2022-05-03

Recruiting

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

NCT05131022Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL)

DrugBexobrutideg

Nurix Therapeutics, Inc.

Phase 1

572

Skórzewo, Krakow, Wroclaw, Warsaw, Katowice, Lublin

2022-04-13

Active, closed

LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women

NCT05303636Change in Bone Mineral Density, Bone Loss

DrugDrospirenone

Insud Pharma

Phase 4

1,536

Bialystok, Katowice, Krakow, Lodz, Warsaw

2022-03-28

Active, closed

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

NCT05317416Multiple Myeloma

DrugsElranatamab·Lenalidomide

Pfizer

Phase 3

854

Skórzewo, Katowice, Gdansk, Poznan, Warsaw, Wroclaw

2022-03-25

Active, closed

COMBINE-INTERVENE: COMBINEd Ischemia and Vulnerable Plaque Percutaneous INTERVENtion to Reduce Cardiovascular Events

NCT05333068Multivessel Coronary Artery Disease, Ischemia, Vulnerable Plaque, Coronary Artery Disease

Diagram B.V.

Not applicable

1,223

Katowice, Krakow, Lubin, Warsaw, Wroclaw

2022-03-16

By invitation

Optimal PeriproCeduraL AnticOagulation in Structural Transseptal Interventions

NCT05305612Mitral Regurgitation, Atrial Fibrillation, Anticoagulation

National Institute of Cardiology, Warsaw, Poland

Phase 4

410

Gdansk, Katowice, Lublin, Poznan, Warsaw

2022-03-13

Active, closed

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

NCT05100862Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma

DrugsRuxience·Truxima·Zanubrutinib·Obinutuzumab

BeOne Medicines

Phase 3

799

Bydgoszcz, Gdansk, Katowice, Krakow, Poznan, Torun, Warsaw

2022-03-10

Recruiting

A Study of Brentuximab Vedotin in Adults With Hodgkin's Lymphoma

NCT05100056Hodgkin Lymphoma

Takeda

Observational

Wroclaw, Poznan, Krakow, Lublin, Tomaszow Mazowiecki, Warsaw, Gdansk, Katowice

2022-03-08

Recruiting

Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

NCT05156398Migraine

DrugRimegepant

Pfizer

Phase 3

640

Poznan, Krakow, Wroclaw, Lublin, Warsaw, Katowice

2022-02-28

Active, closed

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

NCT05211895Non-Small Cell Lung Cancer

DrugsDomvanalimab·Durvalumab

AstraZeneca

Phase 3

791

Bialystok, Gliwice, Katowice, Lodz, Warsaw, Wroclaw

2022-02-18

Recruiting

A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

NCT04779320Crohn's Disease (CD)

DrugVedolizumab

Takeda

Phase 3

120

Krakow, Wroclaw, Warsaw, Rzeszów, Gdansk, Katowice, Szczecin, Lodz

2022-02-10

Recruiting

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

NCT04879043Multiple Myeloma, Plasma Cell Disorder

DrugHDP-101

Heidelberg Pharma AG

Phase 1/2

Katowice, Krakow, Lodz, Opole, Skórzewo, Torun

2022-02-07

Active, closed

Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

NCT05202509Atherosclerotic Cardiovascular Disease

DrugObicetrapib

NewAmsterdam Pharma

Phase 3

9,541

Bydgoszcz, Chorzów, Elblag, Gdansk, Gdynia, Grodzisk Mazowiecki, Katowice, Krakow

2022-02-07

Recruiting

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

NCT05139017DLBCL, Diffuse Large B-Cell Lymphoma

DrugsZilovertamab vedotin·Granulocyte Colony-Stimulating Factor·Riabni·G-Csf

Merck Sharp & Dohme LLC

Phase 2/3

290

Krakow, Wałbrzych, Wroclaw, Lublin, Warsaw, Gdynia, Słupsk, Katowice

2022-01-14

Active, closed

Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

NCT05201638Multiple Sclerosis, Relapsing-Remitting

DrugIMU-838

Immunic AG

Phase 3

1,100

Katowice, Lublin, Plewiska, Poznan, Warsaw, Zabrze

2022-01-12

Active, closed

Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL

NCT05164341Partial Lipodystrophy

DrugMetreleptin

Chiesi Farmaceutici S.p.A.

Phase 3

Katowice, Krakow

2021-12-17

Active, closed

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)

NCT05156281Relapsing Multiple Sclerosis

DrugsTeriflunomide·Remibrutinib

Novartis Pharmaceuticals

Phase 3

1,007

Plewiska, Bialystok, Glogow Wielkopolski, Katowice, Lublin, Wroclaw, Zabrze

2021-12-13

Active, closed

A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia

NCT04812925Primary Immune Thrombocytopenia

DrugEfgartigimod PH20

argenx

Phase 3

173

Katowice, Nowy Sącz, Skorzewo

2021-11-17

Recruiting

Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)

NCT05065216Acute Stroke, Ischemic Stroke, Stroke

DiaMedica Therapeutics Inc

Phase 2/3

728

Katowice, Krakow, Warsaw, Wroclaw, Zielona Góra

2021-11-07

Active, closed

A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma

NCT04712097Relapsed or Refractory Follicular Lymphoma

DrugsMosunetuzumab·Lenalidomide·Rituximab

Hoffmann-La Roche

Phase 3

478

Gdansk, Gdynia, Katowice, Późna, Warsaw, Wroc?aw

2021-10-27

Recruiting

Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis

NCT04833894Generalized Myasthenia Gravis

DrugEfgartigimod

argenx

Phase 2/3

Gdansk, Katowice, Warsaw

2021-10-26

Active, closed

A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

NCT05083169Multiple Myeloma

DrugsTeclistamab·Pomalidomide·Bortezomib·Daratumumab

Janssen Research & Development, LLC

Phase 3

587

Gdansk, Katowice, Kielce, Lublin, Warsaw, Wałbrzych, Wroclaw

2021-10-14

Recruiting

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

NCT05020236Multiple Myeloma

DrugsDarzalex·Elranatamab·Pomalidomide·Daratumumab

Pfizer

Phase 3

893

Bydgoszcz, Gdansk, Katowice, Poznan, Skorzewo, Warsaw, Wroclaw

2021-10-04

Active, closed

A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT05023980Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsRiabni·Ruxience·Truxima·Pirtobrutinib

Loxo Oncology, Inc.

Phase 3

282

Iwaszkiewicza 5, Lublin, Gdansk, Skorzewo, Biała Podlaska, Bydgoszcz, Katowice, Krakow

2021-09-23

Active, closed

A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

NCT04965493Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsRiabni·Ruxience·Truxima·Pirtobrutinib

Loxo Oncology, Inc.

Phase 3

600

Gdynia, Katowice, Krakow, Lodz, Lublin, Torun, Warsaw

2021-09-20

Active, closed

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

NCT04849728NASH - Nonalcoholic Steatohepatitis

Inventiva Pharma

Phase 3

1,000

Poznan, Wroclaw, Warsaw, Gdynia, Częstochowa, Katowice, Mysłowice, Gdansk

2021-08-19

By invitation

Selatogrel Outcome Study in Suspected Acute Myocardial Infarction

NCT04957719Acute Myocardial Infarction

Viatris Innovation GmbH

Phase 3

25,000

Bialystok, Bielsk Podlaski, Bielsko-Biala, Bydgoszcz, Gdansk, Katowice, Krakow, Krosno

2021-08-14

Recruiting

European Disease Registry on Retinopathy of Prematurity (ROP)

NCT04939571Retinopathy of Prematurity

University Medicine Greifswald

Observational

3,000

Bialystok, Bydgoszcz, Katowice, Olsztyn, Poznan, Warsaw

2021-08-06

By invitation

A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus

NCT04976322Systemic Lupus Erythematosus

UCB Biopharma SRL

Phase 3

760

Bialystok, Bydgoszcz, Katowice, Krakow, Lublin, Poznan, Warsaw, Wroclaw

2021-07-27

Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04910568Multiple Myeloma

DrugsCevostamab·Pomalidomide·Tocilizumab·Daratumumab

Genentech, Inc.

Phase 1

186

Gdansk, Katowice, Późna

2021-07-26

Recruiting

A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

NCT04951622Myasthenia Gravis

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

199

Bydgoszcz, Katowice, Krakow, Lublin, Warsaw

2021-07-15

Active, closed

Safety and Efficacy of the CGuard™ Carotid Stent System in Carotid Artery Stenting

NCT04900844Carotid Artery Stenosis

InspireMD

Not applicable

317

Katowice, Krakow

2021-07-01

Recruiting

HighFLO Study - HighLife Trans-septal Mitral Valve Replacement (TSMVR) Feasibility Study of the Open Cell CLARITY Valve

NCT04888247Mitral Regurgitation

HighLife SAS

Not applicable

Katowice, Warsaw

2021-07-01

Active, closed

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

NCT04915755Neoplasms, Breast

DrugNiraparib

GlaxoSmithKline

Phase 3

Katowice, Krakow, Olsztyn, Poznan, Rzeszów, Siedlce, Szczecin, Warsaw

2021-06-28

Active, closed

Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus

NCT04877691Systemic Lupus Erythematosus

DrugAnifrolumab

AstraZeneca

Phase 3

367

Katowice, Kościan, Krakow, Lodz, Lublin, Nowa Sól, Ustroń, Warsaw

2021-06-08

By invitation

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM

NCT04848506Symptomatic Hypertrophic Cardiomyopathy (HCM)

DrugAficamten

Cytokinetics

Phase 2/3

900

Katowice, Warsaw

2021-05-06

Recruiting

A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.

NCT04752774Spasticity

DrugsDysport·Corabotase

Ipsen

Phase 1/2

240

Gdansk, Katowice, Krakow, Lodz, Oświęcim, Poznan, Sandomierz, Warsaw

2021-04-29

Recruiting

Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

NCT04743141Acute Treatment of Migraine

DrugRimegepant

Pfizer

Phase 3

600

Katowice, Krakow, Poznan, Wroclaw

2021-04-28

Active, closed

DiamondTemp Global Registry

NCT04735016Arrhythmia

Medtronic Cardiac Ablation Solutions

Observational

545

Katowice

2021-04-22

Active, closed

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.

NCT04680052Follicular Lymphoma, Marginal Zone Lymphoma

DrugsTafasitamab·Lenalidomide·Rituximab

Incyte Corporation

Phase 3

654

Brzozów, Katowice, Krakow, Lodz, Lublin, Tomaszów Mazowiecki, Warsaw, Wroclaw

2021-04-15

Active, closed

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

NCT04576156Myelofibrosis

DrugImetelstat Sodium

Geron Corporation

Phase 3

327

Piła, Skórzewo, Katowice, Biała Podlaska

2021-04-12

Active, closed

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis

DrugsPelabresib·Ruxolitinib

Novartis Pharmaceuticals

Phase 3

430

Biała Podlaska, Gdansk, Katowice, Skorzewo, Torun

2021-04-09

Recruiting

COVID-19 Vaccines Safety Tracking (CoVaST)

NCT04834869Adverse Reaction to Vaccine, COVID19 Vaccine

DrugsComirnaty·Spikevax

Masaryk University

Observational

30,000

Katowice

2021-04-01

Active, closed

A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis

NCT04562870Myelofibrosis

DrugSelinexor

Karyopharm Therapeutics Inc

Phase 2

112

Katowice

2021-03-17

Active, closed

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

NCT04586010Relapsing Multiple Sclerosis

DrugsFenebrutinib·Teriflunomide

Hoffmann-La Roche

Phase 3

746

?ory, Bydgoszcz, Katowice, Krosno, Lodz, Lublin, Warsaw, Zabrze

2021-03-17

Active, closed

Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis

NCT04562389Myelofibrosis

DrugsSelinexor·Ruxolitinib

Karyopharm Therapeutics Inc

Phase 3

353

Skórzewo, Torun, Wroclaw, Lublin, Brzozów, Gdansk, Katowice, Wałbrzych

2021-03-11

Active, closed

Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT04666038Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsIdelalisib·Truxima·Pirtobrutinib·Bendamustine

Loxo Oncology, Inc.

Phase 3

238

Iwaszkiewicza 5, Lublin, Gdansk, Gdynia, Brzozów, Bydgoszcz, Katowice, Krakow

2021-03-09

Recruiting

Randomized Study in Children and Adolescents With Migraine: Acute Treatment

NCT04649242Pediatric Migraine

Pfizer

Phase 3

2,100

Wroclaw, Katowice, Krakow, Poznan, Szczecin

2021-01-15

Active, closed

A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

NCT04628494Diffuse Large B-cell Lymphoma

DrugEpcoritamab

Genmab

Phase 3

483

Gdansk, Katowice, Krakow, Lodz, Skorzewo, Wroclaw

2021-01-13

Active, closed

A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

NCT04204616Prurigo Nodularis

DrugNemolizumab

Galderma R&D

Phase 3

500

Bydgoszcz, Chorzów, Częstochowa, Gdansk, Gdynia, Katowice, Krakow, Lodz

2021-01-11

Active, closed

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

NCT04548999Multiple Sclerosis

DrugsOcrelizumab·Methylprednisolone

Hoffmann-La Roche

Phase 3

769

Bydgoszcz, Gdansk, Katowice, Krakow, Lodz, Lublin, Oświęcim, Plewiska

2020-12-03

Active, closed

PARADIGM: Amplatzer Valvular Plug for PVL Closure

NCT04489823Paravalvular Aortic Regurgitation

Abbott Medical Devices

Not applicable

200

Katowice

2020-12-01

Active, closed

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

NCT04544436Multiple Sclerosis

DrugsOcrelizumab·Methylprednisolone

Hoffmann-La Roche

Phase 3

864

Bydgoszcz, Gdansk, Katowice, Lodz, Lublin, Późna, Rzeszów, Szczecin

2020-11-26

Active, closed

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

NCT04623541Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Treatment-naïve High Risk Chronic Lymphocytic Leukemia

DrugsEpcoritamab·Pirtobrutinib·Lenalidomide·Venetoclax

Genmab

Phase 1/2

194

Katowice, Krakow, Skorzewo

2020-11-25

Recruiting

LANDMARK Trial: a Randomised Controlled Trial of Myval THV

NCT04275726Aortic Valve Stenosis

Meril Life Sciences Pvt. Ltd.

Not applicable

988

Krakow, Gdansk, Katowice, Warsaw, Wroclaw

2020-11-04

Active, closed

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis

NCT04544449Multiple Sclerosis, Primary Progressive

DrugsFenebrutinib·Ocrelizumab

Hoffmann-La Roche

Phase 3

985

Bydgoszcz, Katowice, Lodz, Późna, Rzeszów, Warsaw, Wroc?aw, Zabrze

2020-10-26

Active, closed

Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC

NCT04550260Esophageal Squamous Cell Carcinoma

DrugsFluorouracil·Durvalumab·Capecitabine·Cisplatin

AstraZeneca

Phase 3

640

Katowice, Krakow, Lodz, Siedlce, Warsaw

2020-10-19

Active, closed

Myasthenia Gravis Inebilizumab Trial

NCT04524273Myasthenia Gravis

DrugInebilizumab

Amgen

Phase 3

238

Katowice, Krakow, Poznan, Warsaw

2020-10-15

Active, closed

Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT04384484Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma

DrugsLoncastuximab Tesirine·Rituximab·Oxaliplatin·Gemcitabine

ADC Therapeutics S.A.

Phase 3

440

Krakow, Wroclaw, Gdynia, Katowice, Lodz, Opole, Skorzewo, Warsaw

2020-09-16

Active, closed

Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome

NCT04401748Myelodysplastic Syndrome (MDS)

DrugsVenclexta·Azacitidine·Venetoclax

AbbVie

Phase 3

531

Bydgoszcz, Lublin, Warsaw, Gdansk, Katowice, Lodz

2020-09-10

Active, closed

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

NCT04442022Relapsed/Refractory Diffuse Large B-cell Lymphoma

DrugsSelinexor·Rituximab·Dexamethasone·Gemcitabine

Karyopharm Therapeutics Inc

Phase 2/3

501

Krakow, Gdynia, Wroclaw, Katowice, Skorzewo, Warsaw

2020-09-03

Active, closed

Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

NCT04468984Myelofibrosis (MF)

DrugsNavitoclax·Ruxolitinib

AbbVie

Phase 3

330

Piła, Poznan, Krakow, Lublin, Warsaw, Gdansk, Katowice, Lodz

2020-08-31

Active, closed

Linerixibat Long-term Safety, and Tolerability Study

NCT04167358Cholestasis

GlaxoSmithKline

Phase 3

242

Częstochowa, Katowice, Mysłowice, Warsaw, Wroclaw

2020-07-14

Active, closed

Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

NCT04273945Pulmonary Arterial Hypertension

DrugMacitentan

Actelion

Phase 3

935

Bialystok, Bydgoszcz, Gdansk, Katowice, Krakow, Szczecin, Warsaw, Wroclaw

2020-06-30

Recruiting

A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

NCT04219254Solid Tumor, Adult

DrugKeytruda

BioInvent International AB

Phase 1/2

197

Gliwice, Katowice, Lodz

2020-06-29

Recruiting

Comparison of LAA-Closure vs Oral Anticoagulation in Patients With NVAF and Status Post Intracranial Bleeding.

NCT04298723Intracranial Hemorrhages, Atrial Fibrillation (AF), Atrial Flutter

Jena University Hospital

Not applicable

530

Poznan, Bielsko-Biala, Katowice

2020-06-16

Active, closed

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

NCT04224493Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma

DrugTazemetostat

Epizyme, Inc.

Phase 3

599

Skórzewo, Warsaw, Katowice, Krakow, Torun, Wroclaw

2020-06-11

Active, closed

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM

NCT07084896Multiple Myeloma

DrugsNirogacestat·Belantamab mafodotin

GlaxoSmithKline

Phase 1/2

106

Katowice, Lodz, Lublin

2020-06-08

Recruiting

TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention

NCT04294927BRCA1 Gene Mutation, BRCA2 Gene Mutation, RAD51C Gene Mutation, RAD51D Gene Mutation

University Medical Center Nijmegen

Not applicable

3,000

Gdynia, Katowice, Warsaw

2020-03-01

Recruiting

Resting Full-cycle Flow Ratio (RFR) Versus Angiography to Guide Revascularization Strategy in Patients Undergoing Coronary Artery By-pass Grafting (CABG)

NCT04375306Coronary Artery Disease

Diagram B.V.

Not applicable

500

Katowice

2020-02-03

Active, closed

A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis

NCT03997786Moderate-to-severe Chronic Plaque Psoriasis

DrugsTildrakizumab·Etanercept

Sun Pharmaceutical Industries Limited

Phase 2/3

135

Bialystok, Katowice, Lodz, Lublin, Ostrowiec Świętokrzyski, Sosnowiec, Szczecin, Warsaw

2020-01-15

Active, closed

Sperm Selection Strategies and Male-Factor Phenotypes in ICSI

NCT07825584Assisted Reproductive Technology, Assisted Reproductive Technology Outcomes

Center for Reproductive Medicine Bocian

Observational

12,561

Poznan, Lublin, Warsaw, Rzeszów, Bialystok, Gdansk, Katowice, Szczecin

2020-01-02

Recruiting

Trifecta-Kidney cfDNA-MMDx Study

NCT04239703Kidney Transplant Rejection

University of Alberta

Observational

300

Bialystok, Bydgoszcz, Gdansk, Katowice, Poznan, Szczecin, Warsaw, Wroclaw

2019-12-01

Active, closed

HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

NCT04153149Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

DrugVutrisiran

Alnylam Pharmaceuticals

Phase 3

655

Wroclaw, Lodz, Warsaw, Gdansk, Katowice

2019-11-26

Active, closed

An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis

NCT04130997Relapsing Multiple Sclerosis (RMS)

DrugUblituximab

TG Therapeutics, Inc.

Phase 3

1,100

Katowice, Krakow, Lodz, Olsztyn, Poznan, Warsaw, Zabrze

2019-11-18

Active, closed

Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

NCT04126200Multiple Myeloma

DrugsFeladilimab·Nirogacestat·Belantamab mafodotin·Isatuximab

GlaxoSmithKline

Phase 1/2

208

Gdansk, Katowice, Lodz, Lublin

2019-10-07

Recruiting

A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects

NCT03893045Iron Deficiency Anemia

DrugsIron sucrose·Ferumoxytol

AMAG Pharmaceuticals, Inc.

Phase 3

Bydgoszcz, Dębica, Katowice, Rzeszów, Warsaw, Wroclaw

2019-09-18

Active, closed

Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury

NCT03992404Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury

DrugXeomin

Merz Pharmaceuticals GmbH

Phase 3

603

Katowice, Krakow, Lodz, Lublin, Warsaw, Wroclaw

2019-09-16

Active, closed

Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia

NCT04119050Warm Autoimmune Hemolytic Anemia

DrugNipocalimab

Janssen Research & Development, LLC

Phase 2/3

118

Bialystok, Gdansk, Katowice, Lodz, Opole, Warsaw

2019-08-15

Recruiting

Expanded Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in Patients With Moderate-severe or Severe Mitral Regurgitation and at High Surgical Risk

NCT04029363Mitral Regurgitation

HighLife SAS

Not applicable

120

Gdansk, Katowice, Poznan, Warsaw

2019-05-28

Active, closed

A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

NCT03811561Diabetes Mellitus, Type 2

DrugSemaglutide

Novo Nordisk A/S

Phase 3

1,500

Bialystok, Bydgoszcz, Chorzów, Gdansk, Katowice, Krakow, Lodz, Poznan

2019-05-08

Active, closed

A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis

NCT03900429NASH - Nonalcoholic Steatohepatitis

DrugResmetirom

Madrigal Pharmaceuticals, Inc.

Phase 3

1,759

Częstochowa, Gdansk, Gdynia, Katowice, Lodz, Poznan, Skórzewo, Warsaw

2019-03-28

Active, closed

Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

NCT03833154Carcinoma, Non-Small-Cell Lung

DrugDurvalumab

AstraZeneca

Phase 3

724

Bydgoszcz, Elblag, Gdansk, Katowice, Lodz, Warsaw

2019-03-06

Active, closed

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

NCT03650114Relapsing Multiple Sclerosis

Drugs13-valent pneumococcal conjugate vaccine·23-valent pneumococcal polysaccharide vaccine·Ofatumumab

Novartis Pharmaceuticals

Phase 3

1,882

Bydgoszcz, Gdansk, Glogow Wielkopolski, Katowice, Kielce, Lodz, Poznan, Rzeszów

2018-12-28

Recruiting

Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

NCT03838926Relapsed or Refractory Hematologic Malignancies

DrugTrichostatin A

Vanda Pharmaceuticals

Phase 1

Biała Podlaska, Katowice, Krakow, Opole, Skorzewo, Warsaw, Wroclaw

2018-09-27

Active, closed

Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

NCT03553836Melanoma

DrugsKeytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

976

Poznan, Bydgoszcz, Krakow, Warsaw, Rzeszów, Gdansk, Bielsko-Biala, Katowice

2018-09-12

Active, closed

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

NCT03398135Ulcerative Colitis (UC)

DrugsSkyrizi·Risankizumab

AbbVie

Phase 3

1,242

Bydgoszcz, Torun, Krakow, Wroclaw, Warsaw, Sopot, Katowice, Tychy

2018-08-28

Active, closed

A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

NCT03519945Ulcerative Colitis

DrugMirikizumab

Eli Lilly and Company

Phase 3

1,058

Będzin, Bydgoszcz, Elblag, Katowice, Krakow, Lublin, Nowy Targ, Olsztyn

2018-07-18

Active, closed

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

NCT03466411Crohn's Disease

DrugsGuselkumab 1·Guselkumab 2·Guselkumab 3·Ustekinumab

Janssen Research & Development, LLC

Phase 2/3

1,409

Bydgoszcz, Chojnice, Częstochowa, Gdansk, Gdynia, Jelenia Góra, Katowice, Krakow

2018-04-13

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Polish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 29 October 2026. https://priyalifescience.com/clinical-trials-poland/city/katowice

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Poland and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,705 studies in total at the last sync on 28 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 507 of those studies with a site in Katowice.

How many clinical trials are recruiting in Katowice?

270 of the 507 studies on this page are recruiting new participants as of the 28 Oct 2026, 03:18 UTC sync. A further 12 have not yet opened recruitment, 207 are active but closed to new participants, and 18 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Katowice), 507 studies
Phase	Studies	Recruiting	Share
Phase 3	281	132	55.4%
Phase 2	94	53	18.5%
Not applicable	46	26	9.1%
Observational	26	20	5.1%
Phase 2/3	22	14	4.3%
Phase 1/2	18	13	3.6%
Phase 1	11	7	2.2%
Phase 4	9	5	1.8%

Most active sponsors

Lead sponsors with the most studies (Katowice)
Lead sponsor	Studies	Recruiting
AstraZeneca	27	17
Pfizer	23	17
Hoffmann-La Roche	20	7
Janssen Research & Development, LLC	17	7
argenx	16	9
Eli Lilly and Company	16	13
Sanofi	15	5
Bristol-Myers Squibb	12	6
Merck Sharp & Dohme LLC	12	8
The Jerzy Kukuczka Academy of Physical Education in Katowice	12	3

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.